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Abstract 
Genetic diversity of the Organic Cation Transporter 1 gene within the Cape Coloured 
Population 
 
B. Pearce 
MSc Thesis, Department of Biotechnology, University of the Western Cape 
 
The aim of this study was to investigate the genetic diversity of the SLC22A1 gene 
and to deduce its possible pharmacogenetic implications within the Cape Coloured 
population of South Africa; a uniquely admixed population of immigrant Europeans, 
Asians and the indigenous populations. Recent studies have reported an abundance of 
polymorphic variants within this solute carrier transporter gene encoding for the 
organic cation transporter 1, as well as evidence linking these variants to an effect on 
metformin uptake. 
This study included establishing baseline frequency distribution of previously 
reported alleles for 20 SNP variants within the SLC22A1 gene, as well as the 
development of SNaPshot® and Multiplex AS-PCR genotyping assays, and also 
exploring the possibility of using High-resolution melt (HRM) analysis as a cost-
effective alternative for SNP genotyping.  
Ethics clearance was obtained from the Ethics Committee of the University of the 
Western Cape. Biological samples in the form of buccal (oral) swabs were collected 
from 132 unrelated voluntary donors from the Cape Coloured population residing in 
the Cape Metropolitan area.  
Two SNaPshot® Multiplex Systems were specifically designed for the study, 
successfully optimized and used for genotyping. Hundred genetic profiles were then 
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generated for a total of 20 SNP variants on SLC22A1 gene, using this primer 
extension-based genotyping method that enables multiplexing up 10 SNPs. 
Population genetics data obtained for the investigated SNPs were analysed using 
various statistical analysis software. Important population genetic parameters were 
calculated, and possible pharmacogenetics implications were then discussed. Among 
others, allelic and genotypic frequencies, as well as linkage disequilibrium were 
determined and compared with world populations. Minor deviation from Hardy-
Weinberg equilibrium was observed in the Cape Coloured population. No significant 
Linkage Disequilibrium between the investigated SNPs was observed in this 
population. 
A Multiplex allele specific – PCR (MAS-PCR) genotyping system was successfully 
designed and optimized for the genotyping of 10 SNPs from the SLC22A1.  This 
system, also developed specifically for this study, was made of 2 multiplexes each 
covering 5 SNPs. It is an inexpensive genotyping assay that allows for efficient 
discrimination of SNP polymorphisms in one reaction tube with standard PCR 
conditions. 
A pilot study was conducted to explore the possibility of using High-resolution melt 
(HRM) analysis as a cost-effective alternative for SNP genotyping. In addition to 
genotyping, HRM analysis can be used to scan large numbers of samples for novel 
genetic variations. 
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Chapter One 
 
Literature Review 
 
1.1. Introduction 
Human genetics commonly refers to the study of gene inheritance patterns occurring 
in human beings. Human genetics includes a multitude of overlapping fields. These 
include classical genetics, cytogenetics, molecular genetics, biochemical genetics, 
genomics, population genetics, developmental genetics, clinical genetics, and genetic 
counselling (Nussbaum et al, 2007). Studying human genetics is useful in that it can 
provide possible solutions to questions about human nature. From this we might also 
elucidate diseases, and develop effective disease treatment, and understand the 
genetics and mechanics of human life. (Nussbaum et al, 2007) 
 
1.1.1. Major forms of Human genetic variation 
Genetic variation has been defined as the existence of two or more genetic variants at 
a considerable occurrence in a specific population. This includes alleles, phenotypes, 
sequence variants and chromosomal structure variants (Strachan & Read, 2004). 
Human genetic variation may be subdivided into two major forms, namely sequence 
polymorphisms and length polymorphisms. Sequence polymorphisms are defined as a 
change in one or more bases in the DNA sequence at a specific locus.  Length 
polymorphisms are defined as variations in the length of a repetitive DNA sequence 
(Rudin & Inman, 2002; Butler, 2005).  Many techniques have been developed to test 
for and characterise DNA polymorphisms, including restriction fragment length 
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polymorphisms (RFLP) analysis, single nucleotide polymorphism (SNP) analysis, 
short tandem repeat sequences (STRs) and mitochondrial DNA (mtDNA) sequencing. 
 
1.1.2. Single Nucleotide Polymorphisms 
Single nucleotide polymorphisms (SNPs) are the most abundant form of genetic 
variation in the human genome, with a total of approximately 12 million SNPs 
identified (Brockmoller and Tzvetkov, 2008).  SNPs are generally used as markers to 
aid identification of the genes underlying complex diseases (Shastry, 2007; Caulfield, 
2001). As the name suggests, the site of variation lies within a single nucleotide which 
may undergo specific mutations termed base substitutions in which one nucleotide is 
replaced by another. Two forms of base substitutions can occur, transition 
substitutions or transversion substitutions. Transition substitution occurs between 
either two purines, Adenosine (A) and Guanine (G), or between two pyrimidines, 
Thymine (T) and Cytosine (C) and is also thought to have resulted in two thirds of all 
SNPs in the human genome. Transversion substitutions occur when shift from a 
purine to pyrimide, or vice versa, is evident, such as an A to T shift. (Smith, 2002) 
 
It is accepted that most SNPs are not thought to impact of gene function. However, 
SNPs found within coding regions (cSNPs) or within regulatory regions are 
considered to be significantly more likely to result in functional changes (Gaudet et 
al., 2007). cSNPs found within coding regions are defined as being either 
synonymous or non-synonymous. Synonymous polymorphisms alter the coding 
sequence of the coding region, but that alteration does not result in a change in the 
amino acid encoded by that region. It is thus said to be a “silent” polymorphism. Non-
synonymous polymorphisms, however, alter the coding sequence and thereby a codon 
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change. The result of this is a change in amino acid coded by that region. These are 
referred to as missense mutations and form the basis for genome studies (Gaudet et 
al., 2007). Therefore, detecting SNPs which alter gene function has become critically 
important to a broad spectrum of biological and medical disciplines (Benjedoou, 
2010).  Moreover, because SNPs are the most abundant genetic markers in the human 
genome, they have become useful for genome evolution studies, high density genetic 
maps, disease diagnostics, association studies and marker-assisted selection (Gaudet 
et al, 2007). 
 
1.2. Interindividual Variability and Membrane transporters 
It has been established that genetic interindividual variability, genetic variation 
between members the same population, plays a significant role in drug response and 
toxicity (Choi & Song, 2008). These variations may be as a result of numerous 
factors; which include genetic, environmental, physiological and pathophysiological 
(Eichelbaum et al, 2006). It is estimated that genetic factor may account for as much 
as 95% of interindividual variability in drug response and effects (Eichelbaum et al, 
2006; Evans & Relling, 2004; Weinshilboum, 2003).  
 
A prodigious expanse of interindividual variability; resulting from genetic, 
environmental, physiological and pathophysiological factors, exists in drug response 
and toxicity (Choi and Song, 2008). It is estimated that between 15 and 30% of 
interindividual variation in drug disposition and response is a result of genetic factors. 
Novel genetic variations in drug transporters, drug targets, effector proteins and 
metabolizing enzymes, have been discovered over the last decade as a result of the 
improvement of genotyping assays and technologies (Avery et al, 2009).  
 
 
 
 
4 
 
 
Recently, much attention has been focused on the genetic variation of drug 
transporters. This is a result of the roles these transporters play in gastrointestinal 
absorption, biliary and renal elimination and distribution to target sites of their 
specific substrates (Choi and Song, 2008). Moreover, emerging pharmacogenetic 
evidence suggests that membrane transporters are subject to both genotypic and 
phenotypic variation. Additionally, it is also suggested that variation in drug 
transporters may bet he underlying cause of interindividual variability in 
pharmacokinetic disposition, efficacy and toxicity of drug transporter substrates (Choi 
and Song, 2008).  
 
Variations in drug transporters are thus believably responsible for, to a great extent, 
the interindividual variability in pharmacokinetic disposition, efficiency, and toxicity 
of drug transporter substrates (Choi & Song, 2008). The organic cation transporter 
(OCT) family contains three subtypes of facilitated transporters called OCT1, 
encoded by SLC22A1, OCT2 (SLC22A2) and OCT3 (SLC22A3) (Koepsell et al, 
2007). 
 
1.2.1. Drug Transporters 
Membrane transporters are crucial for the maintenance of cellular and organismal 
homeostasis and act by importing essential nutrients for cellular metabolism and by 
exporting waste products and toxic compounds (Leabman et al, 2003). Furthermore, 
membrane transporters are also important in drug response as they are major 
determinants of drug absorption, distribution and elimination, as well as providing the 
targets for many commonly used drugs (Leabman et al, 2003). The ATP-binding 
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Cassette (ABC) transporters and Solute Carrier (SLC) transporters are the two major 
superfamilies of membrane transport proteins (Leabman et al, 2003). The ABC 
transporters include MDR-1 protein, responsible for the pumping of xenobiotics from 
cells, while the SLC transporters are responsible for the uptake and importing of 
neurotransmitters, nutrients, heavy metals and other substrates into cells (Leabman et 
al, 2003; Benjeddou, 2010) 
 
1.2.2 Genetic Polymorphisms of Solute Carrier Transporters 
SLCs are mutually regulated by exogenous and endogenous expressional factors and 
they are influenced by genetic polymorphisms. Genetic polymorphisms affect the 
expression and transport activity of these transporter genes. Many polymorphisms 
have been identified as the factors contributing to the interindividual variation in the 
disposition, distribution and response to substrate drugs (Kerb et al, 2002; Shu et al, 
2003)  
 
It has been reported, by numerous studies, that polymorphic variations exist within the 
SLC22A superfamily from different ethnic groups. Kerb et al. (2002) has reported 
that 25 single nucleotide polymorphisms (SNPs) have been identified within 57 
Caucasian individuals in human SLC22A1. Furthermore, three of the SNPs (R61C, 
C88R, and G401S) showed reduced transport activities as they were non-synonymous 
variants. A total of 15 protein-altering variants from SLC22A1 from diverse ethnic 
backgrounds were reported by Shu et al. (2003). Further findings indicated that four 
SNPs (R61C, G220V, G401S, and G465R) showed reduced transport function, 
whereas S14F exhibited increased transport function (Shu et al, 2003). Two non-
synonymous SNPs found in Korean and Japanese populations (P283L and P341L) 
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showed reduced transport activity (Sakata et al, 2003; Takeuchi et al, 2003). 
Conversely, some non-synonymous SNPs (S14F, S189L, P341L, M420del) showed 
diverse functional changes depends on the substrates examined, for example MPP+, a 
toxic compound implicated in cell death, and the anti-diabetic drug metformin. 
Therefore, depending on the substrate administered, genetic variants within Organic 
Cation Transporter 1 (OCT1) may also differ pharmacokinetically (Choi & Song, 
2008). 
 
Kang et al. (2007) identified three SNPs (M165I, R400C, K432Q) from eight amino 
acid changing variants of SLC22A2, which displayed reduced transport activity.  
Furthermore, separate studies have come to the conclusion that variants (T199I and 
T201M) in SLC22A2, identified in Japanese and Korean populations, showed a 
significant decrease in MPP＋ and metformin uptake (Leabman et al, 2002; Song et 
al, 2008). The A270S variant has been identified in all ethnic groups, and has the 
highest allele frequency. The Km for MPP＋ and Ki value for TEA inhibition of 
MPP＋ uptake was doubled (Leabman et al, 2002; Fujita et al, 2006). Kang et al. 
found that the intrinsic clearance of MPP＋ was decreased more than 20-fold in 
A270S overexpressing oocytes compared with that of the reference group. 
Interestingly, this indicated that the Vmax of Organic Cation Transporter 2 (OCT2), 
rather than binding affinity itself, was more greatly affected by this variant.  
 
Conversely, in SLC22A3, several genomic variants (R120R and A411A) have been 
identified which do not cause amino acid substitutions (Lazar et al, 2003). Therefore, 
in relation to genetic polymorphisms, limited information is available for functional 
changes in Organic Cation Transporter 3 (OCT3). Therefore, our understanding of 
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interindividual drug responses and the pharmacokinetics of cationic drugs is aided by 
the information gained about the functional genetic polymorphisms of the Organic 
Cation Transporter family.  
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Table 1.1. Summary of published medically relevant SNPs  
SNP ID Family Effect Drug Disease 
rs622342 SLC22A1 Efficacy metformin
a,b,d
 Diabetes Mellitus 
rs1123617 SLC14A2 Efficacy Nifedipine* Hypertension 
rs4149056 SLCO1B1 Other Methotrexatec* Precursor CLLL 
rs11045819 SLCO1B1 Efficacy fluvastatin
a
 Hypercholesterolemia 
rs1051266 SLC19A1 Toxicity/ADR methotrexate
c
 Psoriasis 
rs1051266 SLC19A1 Efficacy methotrexate
c
 Arthritis, Rheumatoid 
rs4795541 SLC6A4 Efficacy,Toxicity/ADR Escitalopram* Depression,Depressive Disorder 
rs4149081 SLCO1B1 Toxicity/ADR methotrexate
c
 Precursor CLLL 
rs11045879 SLCO1B1 Toxicity/ADR methotrexate
c
 Precursor CLLL 
rs2306283 SLCO1B1 Other repaglinide
a
   
rs2306283 SLCO1B1   pravastatin
a
   
rs25531 SLC6A4 Efficacy Fluoxetine* Depressive Disorder, Major 
rs316019 SLC22A2 Toxicity/ADR cisplatin
a,c
 Neoplasms 
rs4149056 SLCO1B1   nateglinide
a
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rs4149056 SLCO1B1 Toxicity/ADR Simvastatin* Muscular Diseases,Myopathy, Central Core 
rs4149056 SLCO1B1 Efficacy repaglinide
a
   
rs4149056 SLCO1B1 Efficacy Repaglinide
a
   
rs4149015 SLCO1B1 Efficacy pravastatin
a
   
rs12422149 SLCO2B1 Efficacy Montelukast* Asthma 
rs714368 SLC22A16 Dosage,Toxicity/ADR doxorubicin,doxorubicinol* Breast Neoplasms 
rs2301159 SLC10A2 Toxicity/ADR docetaxel,thalidomide* Prostatic Neoplasms 
Where CLLL is an abbreviation for Cell Lymphoblastic Leukemia-Lymphoma 
a
 Fahrmayr,et al, 2010 
b
 Kroetz et al, 2010 
c
 Nakanishi & Tamai, 2011 
d 
Choi and Song, 2008 
* Pharmacogenomics Knowledgebase (http://www.pharmgkb.org/gene/PA329)
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1.2.3. Solute Carrier Transporters (SLC) 
The Solute Carrier Transporter superfamily is comprised of over 300 members further 
subdivided into 47 families. These transporters are primarily expressed in the liver, 
lungs, kidneys and intestines but can be found in most tissues.  They are localized to 
either the basolateral or apical plasma membrane of polarized cells but can be 
expressed in mitochondria and other organelles (Wojtal et al, 2009; Chen et al, 2001; 
Sweet et al, 2001). Because they are membrane-associated transporters, they are 
crucial for the facilitating the passage of solutes such as peptide, amino acids, bile 
acids, xenobiotics, ions, drugs and other biological compounds (Hediger et al, 2004; 
Koepsell et al, 2007).  
 
The SLCs are critically involved in drug absorption, primarily in the intestine, and are 
therefore major determinants of drug distribution and the pharmacokinetic 
characteristics of many drugs (Meier et al, 2007). The majority of transporters in the 
SLC22 family are polyspecific, indicating that they are specific for a myriad of 
substrates. They are further subdivided into three groups; organic cation transporters 
(OCTs), organic anion transporters (OATs) and organic zwitterion/cation transporters 
(OCTNs) (Meier et al, 2007). However, for the purpose of this study, the OCTs will 
be focused upon. 
 
The OCTs, include OCT1 (SLC22A1), OCT2 (SLC22A2) and OCT3 (SLC22A3). 
Human OCTs (hOCT1, hOCT2, hOCT3) facilitate the electrogenic transport of small 
organic cations, many having different molecular structures, independent of sodium 
gradient. Included in these organic cation substrates are therapeutics (Metformin), 
endogenous compounds (dopamine) and toxic substances (TEA) (Kang et al, 2007; 
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Leabman et al, 2002; Fujita et al, 2006; Song et al, 2008). Clustered together on the 
long arm of chromosome 6 are the genes encoding the human isoforms of the three 
organic cation transporters (hOCT1, hOCT2, hOCT3). Furthermore, numerous SNPs 
have been identified in these three genes by various population genetics analyses 
(Tzvetkov et al, 2009).   
 
1.3. Organic Cation Transporter Genes 
1.3.1 Structure of the OCTs 
Organised within the SLC22A superfamily, three isoforms of OCT exist; these 
include OCT1, OCT2 and OCT3. Similar membrane topologies are noted between 
homologues of this family. These consist of 12 transmembrane domains (TMDs), an 
intracellular N-terminus, a large glycosylated extracellular loop between TMD 1 and 
2, a large intracellular loop with phosphorylation sites between TMDs 6 and 7, and an 
intracellular C-terminus. (Koepsell et al, 2007; Gorboulev et al, 2005; Gorboulev et 
al, 1999) 
 
 Substrate specificities have been proposed, by use of the tertiary structure model of 
the transmembrane helixes (TMHs) of rat Oct1 and site-directed mutagenesis of 
amino acids, substrate-binding cleft and critical amino acids. The substrate-binding 
pocket is believed to consist of three amino acids on the fourth TMH (W218, Y222, 
and T226), three amino acids on the tenth TMH (A443, L447, and Q448), and one 
amino acid on the eleventh TMH (D475). These amino acids are located in one region 
surrounding a large cleft which opens to the intracellular side. This region is highly 
conserved among the subtype of the OCT superfamily (Popp et al, 2005; Gorboulev et 
al, 2005; Gorboulev et al, 1999).  
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The organic cation transporter 1 (OCT1) was first cloned from rats in 1994 
(Grundemann et al, 1994) and has subsequently been cloned from humans, rabbits, 
and mice (Green et al, 1999; Terashita  et al, 1998; Zhang et al, 1997). The 
homologues of OCT1, OCT2 and OCT3 have also subsequently been cloned from 
humans, rabbits, rats, and mice (Green et al, 1999; Terashita  et al, 1998; Zhang et al, 
1997; Gorboulev et al, 1997; Okuda et al, 1996; Mooslehner & Allen, 1999; 
Grundemann et al, 1998; Kekuda et al, 1998; Wu et al, 2000).  
 
 
Figure 1.1: Human Organic Cation Tranporter 1 amino acid organisation at the membrane. 
(Wright & Dantzler, 2004) 
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Figure 1.2:  Membrane organisation of the human Organic Cation Transporter 2 protein. (Pelis 
et al, 2006) 
 
1.3.2 Tissue Distribution of OCTs 
The OCT isoforms mediate the electrogenic transport of small organic cations. These 
molecules have been determined to be structurally unrelated, however, they share 
broad substrate specificity and they include model organic cations (TEA, decynium-
22), clinically important therapeutic drugs (metformin, procainamide, cisplatin, 
citalopram, cimetidine), endogenous compounds (dopamine, norepinephrine), and 
toxic substances (RHPP＋, HPP＋, MPP＋) (Koepsell et al, 2007; Gorboulev et al, 
1997; Zhang et al, 1997; Kang et al, 2006). 
 
 
 
 
 14 
However, despite the sequence homology and broad substrate specificity, OCT1 and 
OCT2 transporters are discernible from each other as a result of their selective 
substrates, as well as the difference in tissue distribution (Arndt et al, 2001; Koepsell 
et al, 1999). The OCT subtypes show distinctive tissue distributions. OCT1 is 
primarily expressed in the sinusoidal membrane of hepatocytes and is present in the 
epithelial membrane of the intestine at minimal levels. OCT2 is primarily expressed 
in the basolateral membrane of the kidney proximal tubules. OCT3 generally has an 
extensive tissue distribution as it is found in numerous organs, skeletal muscles, blood 
vessels, and the placenta (Koepsell et al, 2007).   
 
1.3.3 Physiological role of OCTs 
OCT1, OCT2 and OCT3 are considered to play an important role in the biliary and 
renal excretion of their substrates and the distribution of organic cationic drugs in the 
liver, kidney, heart, and brain (Jonker & Schinkel, 2004). This notion is largely based 
on their substrate specificities and tissue distributions. Knockout mouse models were 
generated for the Slc22a1, Slc22a2, and Slc22a3 genes to illuminate the physiological 
function of OCTs. Oct1-, Oct2-, and Oct3-deficient mice were viable and displayed 
no obvious phenotypic abnormalities (Jonker & Schinkel, 2004; Jonker et al, 2003; 
Zwart et al, 2001). Conversely, Oct1-knockout mice showed considerably reduced 
hepatic uptake of TEA and metformin (Jonker et al, 2001; Wang et al, 2002; Wang et 
al, 2003). In Oct1/Oct2 double-knockout mice, the renal secretion of TEA was 
eradicated and significantly amplified plasma levels of TEA were noted (Jonker et al, 
2003). These animal studies accentuated the role of the OCT superfamily in hepatic 
and renal secretion of organic cations (Choi & Song, 2008).     
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1.3.4 Regulation of OCTs 
Regulation of OCTs is affected on an MRN as well as a protein level and as such 
dictates the cellular tissue distribution of the substrate drugs. Ciarimboli et al. (2005) 
have proposed mechanisms of posttranscriptional regulation of OCT1 by its 
phosphorylation status and several molecules including activators or inhibitors of 
protein kinase A (PKA), Src-like p56, and calmodulin (CaM) have been confirmed to 
modify OCT activity (Cetinkaya et al, 2003; Ciarimboli et al, 2005; Denk et al, 2004; 
Biermann et al, 2006). It has recently been reported that the promoter of contains two 
adjacent DNA-responsive elements (DR-2) for hepatocyte nuclear factor-4a (HNF-
4a). Additionally, HNF-4a effectively activated a luciferase reporter construct 
containing the OCT1 promoter.  Furthermore, mRNA expression of OCT1 was 
amplified by the over expression of HNF-4a (Saborowski et al, 2006).  
 
 
Figure 1.3: Schematic illustration of transcriptional and post trancriptional regulation of OCT1 
(Choi & Song, 2008). 
 
 OCT 2 transcription is activated through basal promoter elements such as the CAAT-
box, located at -92 and the E-box, located at -87. Human upstream stimulatory factor-
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1 (USF-1) has been found to transactivate OCT2 promoter activity (Asaka et al, 
2007).     
 
 
Figure 1.4: Schematic illustration of transcriptional and post trancriptional regulation of OCT2 
(Choi & Song, 2008) 
 
1.3.5. Organic Cation Transporter One 
1.3.5.1. Genetic Variation in OCT1  
Approximately 20 SNPs have been identified in the SLCs (Fahrmayr,et al, 2010;  
Kroetz et al, 2010; Nakanishi & Tamai, 2011; Choi and Song, 2008; 
Pharmacogenomics database). The specified data suggests that although more 
variations (polymorphisms) exist in the SLC superfamily, only a few are medically 
relevant. More specifically for OCT1, only one SNP (rs622342) is highlighted by the 
data proposed by the Pharmacogenomics Knowledgebase. RS622342 (SLC22A1) was 
determined, by Becker et al. (2009) to have a significant effect on the efficacy of 
metformin uptake in Type-2 Diabetes Mellitus patients.  
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Figure 1.5: Red indicates non-synonymous amino acid changes, indels (insertions and deletions) 
are indicated in blue, and synonymous changes in green. Exon(s) are indicated by black outlines. 
(http://pharmacogenetics.ucsf.edu/cgi-bin/Gene.py?hgncSymbol=SLC22A1) 
 
However, recent studies have reported an abundance of polymorphic variants in the 
SLC22A1 gene, each having an effect on metformin uptake. Kerb et al. (2002) 
identified 25 SNPs in SLC22A1. Shu et al. (2003) identified 15 non-synonymous 
variants in SLC22A1 from different ethnicities. Voluminous other polymorphisms 
have been identified by Sakata et al.(2004), Itoda et al. (2004), and Kang et al. 
(2007). Table 1.2. (below) is a summary of the clinically relevant variants in 
SLC22A1. All information in the table was taken from the PMT database.  
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Table 1.2. Single nucleotide polymorphisms previously reported as clinically relevant for OCT 1 
in different population groups, included are the allele frequencies for each locus.  
 
SNP 
 
African 
American 
 
Caucasian 
 
 
Asian 
 
Mexican 
 
Pacific 
Islander 
 
Sub-Saharan 
African 
 
RS_2282143 
 
 
C- 0.918 
T- 0.082 
 
C-1 
T- 0 
 
C-0.883 
T- 0.117 
 
C – 1 
T -0 
 
C – 1 
T- 0 
 
C- 0.916 
T- 0.084 
 
RS_36103319 
 
G- 0.995 
T- 0.005 
 
G-1 
T- 0 
 
G-1 
T- 0 
 
G-1 
T- 0 
 
G-1 
T- 0 
 
G- 0.997 
T- 0.003 
 
RS_34104736 
 
C-1 
T- 0 
 
C-0.995 
T- 0.005 
 
C-1 
T- 0 
 
C-1 
T- 0 
 
C-1 
T- 0 
 
C- 0.998 
T- 0.002 
 
RS_35167514 
 
A - 0.971 
Del - 0.029 
 
A - 0.815 
Del - 0.185 
 
A - 1 
Del - 0 
 
A - 0.786 
Del - 0.214 
 
A - 1 
Del - 0 
 
A - 0.895 
Del - 0.105 
 
RS_34130495 
 
G - 0.993 
A - 0.007 
 
G - 0.989 
A - 0.011 
 
G - 1 
A - 0 
 
G - 1 
A - 0 
 
G - 1 
A - 0 
 
G - 0.992 
A - 0.008 
 
RS_2297373 
 
C - 1 
G - 0 
 
C - 1 
G - 0 
 
C - 1 
G - 0 
 
C - 1 
G - 0 
 
C - 1 
G - 0 
 
C - 1 
G - 0 
 
RS_16891138 
 
A - 0.965 
C -  0.035 
 
A-1 
C - 0 
 
A-1 
C - 0 
 
A-1 
C - 0 
 
A-1 
C - 0 
 
A -  0.951 
C -  0.049 
 
RS_34305973 
 
T - 0.971 
Del - 0.029 
 
T - 0.815 
Del - 0.185 
 
T - 1 
Del - 0 
 
T - 0.786 
Del - 0.214 
 
T - 1 
Del - 0 
 
T - 0.895 
Del - 0.105 
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1.4. Genotyping Techniques 
1.4.1. PAMSA Genotyping and Limitations 
PCR Amplification of Multiple Specific Alleles (PAMSA) involves the use of at least 
two allele-specific primers in the same reaction and allows for the detection of all 
SNP alleles, at that locus, present in a sample (Ishiguro et al, 2005; Hansson and 
Kawabe, 2005). The principle behind allele-specific PCR has remained constant while 
the execution of the method has been altered and improved numerous times in recent 
years. Many PAMSA methods allow for the discrimination of alleles by gel 
electrophoresis. Dutton and Sommer (1999), described a PAMSA method in which 
one allele-specific primer was 31 nucleotides longer than the other. A variant of the 
PAMSA method is the bidirectional-PASA, described by Liu et al. (1997). In this 
method one allele is amplified n one direction while the other allele is amplified in the 
opposite direction. This method, however, requires four primers and rigorous 
optimization (Liu et al, 1997; Sasvari-Szekeley et al, 2000; Waterfall and Cobb, 
2001; Waterfall and Cobb 2002). 
 
 In another variation of the PAMSA method, described by Okimoto and Dodgson 
(1996), a primer length difference of between 2 and 5 nucleotides was used. Alleles 
 
RS_1867351 
    
   T - 0.737 
C -  0.263 
   
  T - 0.794 
C -   0.206 
 
T - 0.567 
C- 0.433 
   
  T - 0.722 
C -  0.278 
 
T - 0.714 
C - 0.286 
 
 
 
RS_12208357 
 
T - 1 
C - 0 
 
T - 0.928 
C -  0.072 
 
T - 1 
C - 0 
 
T - 0.944 
C -  0.056 
 
T - 1 
C - 0 
 
T - 0.989 
C -  0.011 
Minor alleles and minor allele frequencies for all populations were determined from the NCBI 
1000Genome reference data. 
 
 
 
 
 20 
were resolved on acrylamide gel and the molar ratio of allele-specific primers needed 
to be optimized. In the method described by Gaudet et al. (2007), three unlabelled 
primers were used to amplify specific alleles. The alleles-specific primers included a 
destabilising mismatch within five bases of the 3‟ end and a 5‟ tail of randomly 
selected bases for the amplification of different length PCR products, which were 
resolved on agarose gel.  
 
The addition of a destabilising mismatch and a 5‟ tail was meant to confer higher 
allele specificity and allow for performing PCR without optimization. However, when 
used in multiplex these features, with the exception of the destabilising mismatch, 
reduce the efficacy of the PCR reaction (Edward and Gibbs, 1995; Markoulatos et al, 
2002). Therefore, non-specific amplification became prevalent. It was determined that 
the design of the primers was the cause of non-specific amplification. This is the 
fundamental limitation of this method.  Since a random tail was added to each primer, 
primer-primer interactions, secondary structures and dimerization would have been 
virtually impossible to avoid. Therefore, rigorous optimization of the primer design 
and PCR reaction conditions was necessary.  
 
1.4.2. The SNaPshot®  Genotyping Assay 
Interest in single nucleotide polymorphisms (SNPs) has increased in recent years. 
SNPs are the most abundant type of genetic variation and they are extensively 
characterized within the genome (Bertoncini, et al, 2011; Quintans, et al, 2004). 
Numerous applications in medical genetics, evolutionary genetics and forensics have 
been developed for the estimated 3 million identified SNPs (Evans, et al, 1999; Gwee, 
et al, 2003; Jobling, et al, 2000; Jobling, et al, 1997). Classically, SNP analysis was 
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performed with conventional PCR followed by restriction fragment analysis and gel 
electrophoresis. This method is, however, expensive, time-consuming and requires 
hefty amounts of template DNA (Quintans, et al, 2004). Moreover, countless high-
throughput methods for studying SNPs have been developed in recent years 
including; DNA Microarrays, FRET analysis, MALDI-TOF spectrometry, 
Pyrosequencing and TaqMan assays or Molecular beacons (Syvanen, 2001; 
Carracedo, et al, 1998; Lareu, et al, 2001). The SNaPshot® assay, also based on 
conventional PCR, is a high-throughput method which requires little more than well 
designed primers. It is also less time-consuming and relatively rapid while remaining 
robust and accurate (Syvanen, 1999). 
 
Despite it being exceptionally accurate, efficient and rapid, SNaPshot® genotyping 
remains one of the more expensive methods for outsourced genotyping. The assay is 
based on conventional sequencing but modified for SNP analysis by using chain 
terminator ddNTPs. Primer extension is a stepwise process that involves the 
hybridization of a probe to the bases immediately upstream of the SNP. This is 
followed by a „mini-sequencing‟ reaction, in which DNA polymerase extends the 
hybridized primer by adding a base that is complementary to the SNP nucleotide. This 
newly incorporated base is detected and determines the SNP allele (Syvanen, 2001; 
Tully et al, 1996; Pastinen et al, 1996).  
 
 Since primer extension makes use of highly accurate high-fidelity DNA polymerase 
enzymes, the method is generally very consistent. Primer extension is able to 
genotype most SNPs under very similar reaction conditions, thus in addition, making 
it highly flexible. The primer extension method is used in numerous assay platforms. 
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These platforms use a wide range of detection techniques that include MALDI-TOF 
Mass spectrometry and ELISA-like methods. (Rapley & Harbron 2004) 
 
1.5. Genetic Ancestry and its role in Pharmacogenetics 
Pharmacogenetic discovery and our understanding of population level differences in 
drug response have long been strongly influenced by the concepts of race, ethnicity 
and ancestry (Urban, 2010). Population based studies can help to establish baseline 
frequency distribution of SNPs of genes important in drug metabolism and transport. 
Extrapolations of possible clinical implications of the baseline frequency distribution 
of some of the alleles based on established phenotypic characteristics could guide 
doctors in drug prescription decision-making and possibly provide explanations of 
ethnic-specific adverse effects in metropolitan medical practice (Matimba et al., 
2008). As an example, angiotensin converting enzyme (ACE) inhibitors initially 
designed and tested for the Caucasian American population were blindly used for the 
treatment of hypertension in the African American population. However, no 
compensation was made for the highly prevalent Nitric Oxide Synthase deficiency in 
the African American population (Kalinowski et al, 2004). The medication, therefore, 
was ineffective and deemed dangerous. However, after numerous case-studies and 
genetic analysis an improved form of the drug was developed for the African 
American population (Tate and Goldstein, 2004; Echols and Yancy, 2006). 
 
 Genomic diversity within the African continent, and more specifically within sub-
Saharan Africa, is relatively under-studied, although it is home to significant portion 
of human genomic diversity (Hardy et al., 2008). There is thus a considerable amount 
to be learnt from characterizing human genomic variation in this part of Africa, 
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particularly pertaining to health applications (Hardy et al., 2008). South Africa in 
particular contains a wealth of different population groups. The National 
Biotechnology Strategy Report for South Africa (2002) recognized this fact and 
recommended that the country focus on documenting the genomic diversity contained 
within the local indigenous and immigrant populations (Hardy et al., 2008). The 
country is indeed home to various indigenous populations groups, including the 
Khoisan, Xhosa, Zulu, Venda, and Sotho Pedi groups, the Afrikaaners and the Cape 
Coloured.  
 
The self-designated Cape “Coloured” population is a uniquely admixed population of 
immigrant Europeans, Asians and the indigenous populations (Hardy et al, 2008). 
Furthermore, this population has been shown to have the greatest level of recent 
admixture and almost exclusively resides within the Western Cape region. It is 
currently estimated that 9% of the South African population is comprised of Coloured 
individuals, translating to an estimated four million individuals (Quintana-Murci et al, 
2010). 
 
Admixed groups, such as the Cape Coloured population, share varying proportions of 
different ancestral populations and their genetic complexity can potentially 
complicate biomedical research studies (Via et al, 2009). The mixed ancestry can 
potentially provide the intrinsic variability needed to unravel intricate gene-
environment interactions, which may help explain the population differences in the 
epidemiology of complex disease (Via et al, 2009) and they will, therefore, form the 
focus of this study.  
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1.6. Statistical Analyses 
In addition to the number of people typed, population data sets should include the 
main statistical parameters such as p-value(s) for Hardy-Weinberg equilibrium testing 
and the Bonferroni Value, as well as confidence intervals and heterozygosity value(s). 
Additional quality criteria such as the use of various population-specific indices could 
also be presented. 
 
1.6.1. The Hardy-Weinberg Equilibrium 
The Hardy-Weinberg equilibrium (HWE) states that both the allele and genotype 
frequencies in a population remain constant (Butler, 2005; Nei & Kumar, 2000).  This 
principle assumes that they are in equilibrium from generation to generation unless 
influenced by external selective pressures (Butler, 2005; Nei & Kumar, 2000).   These 
influences include: mutation, mating, selection, population size, random genetic drift 
and gene flow. However, this implies static allele frequencies which assume that 
random mating, no migration, no mutation, infinitely large population sizes and no 
selective pressure occurs which is, of course, invalid as no such population exists 
(Butler, 2005; Nei & Kumar, 2000). However, the HWE is still used to determine 
genotype frequencies. 
 
1.6.2. Observed Heterozygosity 
The number of homozygotes plus the numbers of heterozygotes equals 100% of the 
samples tested in a population (Butler, 2005).  Heterozygosity displays the proportion 
of heterozygous individuals in the population.  The higher the heterozygosity value 
the more allele diversity exists for that particular locus (Butler, 2005).  This therefore 
means that there is less of a chance of a random sample matching.   
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1.6.3. Shannon Index 
Shannon‟s index (I) is a measure of the differentiation across the loci. It measures the 
differentiation based on the number of different alleles present in the sample. This is 
critical to chi-square based statistical test for allele frequency differences (Peakall and 
Smouse, 2009). 
 
1.6.4. Fixation Index 
The Fixation index, also called the Inbreeding Coefficient, is a function of the 
heterozygosity of a locus. It displays values between -1 and 1 where negative values 
indicate excess heterozygosity due to selection for heterozygotes (Peakall and 
Smouse, 2009). Positive values, specifically those near zero, are expected under 
random breeding while positive values approaching 1 are indicative of undetected null 
alleles (Peakall and Smouse, 2009). 
 
Table 1.3. Summary of Genetic Formulae 
HWE 
p
2
 + 2pq + q
2
 = 1, where: p = frequency of the dominant allele 
and, q = frequency of the recessive allele 
Ho 
        n 
1 - ∑ Pi
2
, where Pi = frequency of i
th
 allele in a population of n 
         i          samples 
He 
1 - Sum pi^2  where sum pi^2 is the sum of the squared 
population allele frequencies 
I -1* Sum (pi * Ln (pi)) 
F (He - Ho) / He = 1 - (Ho / He) 
Genetic formulae taken from Butler, 2005; Peakall and Smouse, 2009. 
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1.7. Statistical Analysis Software 
1.7.1. GenAlEx 
Described by Peakall and Smouse, (2006) this an in-MS-Excel application allows for 
various statistical analyses to be calculated, including allele and genotype frequencies, 
the Hardy-Weinberg equilibrium, the Shannon Index and the Fixation Index, as well 
as numerous others. It is also particularly useful for integration of data into various 
formats including GenePop, PHASE, PopGen, and various others. 
 
1.7.2. SNPTools 
Created by Chen et al, SNPTools is an in-MS-Excel application which allows raw 
data to be converted into a format suitable for various population genetics software, 
including Haploview, PLINK, Phase and SNPHAP. Furthermore, it also has built-in 
basic statistical analyses for genetic and epidemiological studies, including Odds 
Ratios, Confidence Intervals and ChiSquare (Chen et al, 2009). 
 
1.7.3. GenePop 
The software GenePop, originally described by Raymond & Rousset (1995), filled a 
gap in practical tools for computing exact tests. Currently, it implements a 
combination of traditional methods and a few more focused developments (Rousset, 
2008). It computes exact tests for Hardy–Weinberg equilibrium, for population 
differentiation and for genotypic disequilibrium among pairs of loci (Rousset, 2008). 
Furthermore, it is able to compute estimates of F-statistics, null allele frequencies, 
allele size-based statistics for microsatellites and number of immigrants by Barton & 
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Slatkin‟s (1986) private allele method. Additionally, it performs analyses of isolation 
by distance from pairwise comparisons of individuals or population samples, 
including confidence intervals for neighbourhood size (Rousset, 2008).  
 
1.7.4. Haploview 
Haploview is used to generate Linkage-Disequilibrium (LD) maps. This is achieved 
through a scoring system designed to make use of the Log of Odds Ratio (LOD) and 
D-prime (D‟) value for each SNP combination (Barrett et al, 2005). The LOD score 
compares the probability of obtaining the same data if the two loci are indeed linked, 
to the probability of observing that same data purely by chance (CardioGenomics, 
2005). Positive LOD scores indicate the presence of linkage, while negative LOD 
scores indicate that linkage is less likely. The amount of LD between the paired SNPs 
is defined as D-prime (0 < d < 1). A value of 0 indicates that the two loci are in 
complete equilibrium and a value of 1 represents the highest amount of disequilibrium 
possible is present (CardioGenomics, 2005).  
 
Therefore, If two SNPs are statistically (LOD>2) related they are coloured in shades 
of red. Darker shades imply more statistically significant the association. This 
indicates an allelic association exists between the SNP pair, thus strongly suggesting 
LD (CardioGenomics, 2005). White squares indicate no relevant statistical 
significance, as D‟ values are below 1, and therefore exhibit no LD. The blue squares 
represent pairwise comparisons where the D‟ value is equal to 1 but no statistical 
relevance exists (CardioGenomics, 2005).  
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1.8. Objectives of the study 
This study forms part of a comprehensive project aimed at investigating the genetic 
diversity of the solute carrier transporter genes and its pharmacogenetic implications 
within the South African and Sub-Saharan African populations, and consequently it 
will contribute in filling the gap of missing important pharmacogenetics data from 
African populations. This includes establishing baseline frequency distribution of 
previously reported alleles for the SLC22A1, SLC22A2, SLC22A3, SLC47A1 and 
SLC47A2, SLC22A4 and SLC22A5 genes, as well as the discovery of new genetic 
variants within the investigated populations for these members of the super-family of 
solute carrier transporters. 
In addition to providing an up-to-date review of the literature concerning the 
pharmacogenetics of the solute carrier transporters (Chapter 1), the specific objectives 
of the study described in this thesis were as follows: 
1- The development of a MAS-PCR genotyping system suitable for the 
genotyping of 10 SNP variants from the SLC22A1 (Chapter 2). It is an 
inexpensive genotyping assay that allows for efficient discrimination of SNP 
polymorphisms in one reaction tube with standard PCR conditions. 
2- The development of SNaPshot® Multiplex Systems for the genotyping of a 
total of 20 SNP variants from the SLC22A1 gene (Chapter 3). This primer 
extension-based genotyping method that enables multiplexing up 10 SNPs. 
3- The generation of important population pharmacogenetic data for the 
investigated SNPs (Chapter 3). Among others, allelic and genotypic 
frequencies, as well as linkage disequilibrium were to be determined and 
compared with world populations. 
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4- Conduct a pilot study to explore the possibility of using High-resolution melt 
(HRM) analysis as a cost-effective alternative for SNP genotyping. 
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Chapter Two 
Development of Allele-Specific PCR Genotyping Multiplexes 
for 10 SNP Variations on the SLC22A1 gene  
 
 
2.1. Introduction 
 
Human organic cation transporters mediate electrogenic transport of small organic 
cations with different molecular structures, independent of sodium gradient. These 
organic cation substrates include therapeutics, endogenous compounds, as well as 
toxic substrates (Kang et al, 2007). Genetic polymorphisms in drug transporter genes 
are increasingly being recognised as possible mechanisms responsible for variation in 
drug response (Shu et al, 2007). Furthermore, pharmacogenetic evidence increasingly 
suggests that membrane transporters are subject to both genotypic and phenotypic 
polymorphisms. Variations in drug transporters are thus believably responsible for, to 
a great extent, the interindividual variability in pharmacokinetic disposition, 
efficiency, and toxicity of drug transporter substrates (Choi & Song, 2008). An 
extensive assortment of methods has been developed to detect these genetic 
variations, including RFLP analysis, SNaPshot® mini-sequencing and direct 
sequencing (Gaudet et al, 2007). However, these methods require expensive 
equipment and rank higher in development costs. The aim for this part of the project 
was therefore to develop inexpensive Multiplex Allele Specific-PCR (MAS-PCR) 
genotyping systems for SNP variations on the SLC22A1 gene. 
The method described in this section is essentially based on the one developed by 
Gaudet et al. (2007) with an improved multiplexing capability. As many as five SNPs 
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have been multiplexed in a single reaction. It is an efficient and inexpensive method 
that enables laboratories to analyse SNPs with standard PCR protocols and is suitable 
for projects with modest budgets or where sophisticated equipment is not available 
(Gaudet et al, 2007). 
 
2.2. Materials and Methods 
 
2.2.1. Sample Collection 
A total of 132 samples in the form of buccal (oral) swabs were collected from healthy, 
unrelated male donors from the Cape Coloured population residing within the Cape 
Town metropolitan area. The term Coloured is used to define a uniquely admixed 
population which was established with contributions from Asian, European and 
indigenous populations (Hardy et al, 2008; Abrahams, et al, 2010). This population is 
known to have the highest rate of admixture in the world and comprises 
approximately 8.9% (~4 million) of the South African population (Ikediobi et al, 
2011). 
 
Ethical clearance for the project was obtained from the Senate Research Committee of 
the University of the Western Cape prior to the sample collection exercise. Once 
swabs were obtained, they were immediately placed into coded envelopes and 
immersed in ice for transport. Samples that were not used immediately were stored at 
-20 °C. 
 
2.2.2. DNA Extraction 
DNA was extracted by a combination of two techniques; salt lysis and 
phenol/chloroform extraction. The cotton tip of each swab was cut off and immersed 
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in an eppendorf tube containing 600 µl salt lysis buffer and 3 µl 20 mg.ml
-1
 Proteinase 
K. The tubes were then incubated at 56 °C overnight. The swabs were discarded and 
the solution containing the DNA was retained. To precipitate the DNA, 200 µl 6M 
NaCl was added and the tubes were vigorously shaken for 15 s. The tubes were then 
centrifuged at 5 000 rpm for 15 min and the supernatant was collected. The 
supernatant was mixed with isopropanol using a 1:1 ratio and incubated at -80ºC for 
30 min. DNA was then pelleted by centrifugation at 14 000 rpm for 30 min. The pellet 
was washed with 100 µl 70% Ethanol and centrifuged at 14 000 rpm for a further 15 
min. The pellets were allowed to dry briefly before being re-suspended in a final 
volume of 30 µl SABAX water. Samples were immediately stored at -20°C for future 
use. The DNA yield was determined using a Nanodrop ND 1000 UV-Vis 
Spectrophotometer.  
 
2.2.3. Primer Design 
All primers were designed using the online software BatchPrimer 3 
(http://probes.pw.usda.gov/cgi-bin/batchprimer3/batchprimer3.cgi), Primo 
(http://www.changbioscience.com/primo) and PrimoSNP 
(http://www.changbioscience.com/primo/primosnp.html). Primers were designed to 
genotype the selected SNPs in two multiplexes, namely Multiplex 1 (M1) and 
Multiplex 2 (M2), each covering 5 SNPs. The primers were designed according to the 
method described by Gaudet et al, 2007. A total of three primers were designed for 
each SNP. This includes a forward primer for each allele, and a common reverse 
primer (Figure 2.1). 
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Figure 2.1: The mechanism of Allele-Specific PCR. Each primer is specific for one allele. A size 
difference is imparted by the addition of 5’-tails and a destabilising mismatch incorporated 
contiguous to the 3’-end. (Gaudet et al, 2007) 
 
 
2.2.4. PCR Amplification 
All DNA samples were diluted to a final concentration of 5 ng.µl
-1
 and used for the 
PCR amplification. The primers used for the PCR amplification for the two 
multiplexes are listed in table 2.1. All primers were synthesized by Integrated DNA 
Technologies (IDT) Munich, Germany. Primers were diluted to a working stock of 2 
μM. PCR amplifications were performed using the Quiagen Multiplex kit in a final 
volume of 10 µl according to manufacturer‟s instructions. PCR amplifications were 
performed using 7 µl of the Qiagen Master Mix and 15 ng DNA adjusted to a final 
volume of 10 µl using RNA-free water. The Qiagen Master Mix used consisted of 1X 
Quiagen Multiplex Master Mix, 2 µM Primers, 0.25X Q Solution, adjusted to 7 µl 
with RNA-free water.  
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Amplification was performed on a GeneAmp 2700 (Applied Biosystems) thermal 
cycler or Supercycler (Kyratec). Thermocycling conditions were as follows: 95°C for 
15 min, 94°C for 30 s, 52.5°C for 60 s, 72°C for 90 s, for a total of 30 cycles, 
followed by 60°C for 30 min and a final hold at 4°C. PCR products were confirmed 
by agarose gel electrophoresis. An aliquot of 3 µl of each product was run on a 2% 
agarose gel at 5V.cm
-1
. The gel was then stained with 0.1 µg.ml
-1
 GelRed and 
visualised under UV light. 
 
2.3. Results and Discussion 
SNP variations were selected from the Pharmacogenomics Knowledgebase, UCSF-
PMT, Japanese SNP and NCBI databases. As listed on the database, primarily SNPs 
which had been annotated and determined to be of clinical relevance were selected. 
However, in the Pharmacogenomics Knowledgebase only one such SNP existed. 
Thus, other databases were consulted for SNPs which have been cited in literature and 
investigated for possible clinical relevance or implications and pharmacogenetic 
importance. The UCSF-PMT database provided a further 7 SNPs, although many had 
not yet been annotated. The final SNPs were selected from a Japanese and NCBI 
databases to complete the ten SNPs for M1 and M2.  
 
2.3.1. Primer Design and Optimization 
Primers for both multiplexes were initially designed manually without using any 
primer software, and based on the PAMSA method principles (Gaudet et al., 2007). 
Initial trials using the PAMSA method for primer design were proven to be less suited 
to multiplex genotyping (data not shown). This approach was therefore improved by 
the use of multiple methods of primer design. The primer sets were then designed 
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using freely available online tools BatchPrimer3, Primo and PrimoSNP. BatchPrimer3 
is an online tool similar to Primer3, which allows multiple primers to be designed at 
once, with the ability to design allele-specific primers (You et al, 2008). It 
automatically inserts the 3‟-mismatch to increase specificity. Allele-specific 
mismatches were manually moved to fall in different positions within the final five 
bases contiguous to the 3‟-end. A tail of random bases was added to the 5‟-end of 
each forward primer, as prescribed by Gaudet et al. (2007). The difference in tail 
length between the allele-specific primers was designed to be between ten and twenty 
bases. The primer orientation was changed when needed in order to further increase 
specificity. The result was three SNP sites having allele-specific forward primers and 
two SNP sites having allele-specific reverse primers.    
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Table 2.1. Allele-Specific primer sets for 10 SNPs 
SNP Name Orientation Primer Sequence Allele Product Size 
Multiplex 1     
RS_34130495 R 1 GCCATGGGGTAGATGCGGCA T 50 bp 
 R 2 GACTGCTGATCGATGGCCATGGGGTAGATGCGGCG C 70 bp 
 F AGCCCTCATCACCATTGACCG   
     
RS_34104736  F1 GTGCTGGTCAACGCGGTGTC G 100 bp 
 F2 TGTCAGACTGCTGATCGATG GTGCTGGTCAACGCGGTGTT A 120 bp 
 R AGTTGCCCTTGCTGACCAGG   
     
RS_36103319  F1 AAGGGCAACTGGATGGCTGG C 210 bp 
 F2 TGTCAGACTGCTGATCGATG AAGGGCAACTGGATGGCTGT A 230 bp 
 R AGAGAGGAGGCCATTCTAGCC   
     
RS_34305973  F1 AGGTTCACGGACTCTGTGCTC G 250 bp 
 R CAACTTACCAGGTGAGATAAAAATCA   
     
RS_2282143  F1 GCAGACCTGTTCCGCACGCC G 300 bp 
 F2 TGTCAGACTGCTGATCGATG GCAGACCTGTTCCGCACGCT A 320 bp 
 R CTCATCCCACTGGTGATCTCC   
     
Multiplex 2     
RS_683369  F1 TTTTTTTGAATGCGGGCTTCATC  G 70 bp 
 F2 TTTTTTTTTTTTTTTTTTTTTTTTGAATGCGGGCTTCCTG  C 90 bp 
 R GGCCTTTACATACCTGTCTGC    
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RS_35167514  F1 GCAGCCTGCCTCGTCA T 90 bp 
 R TCCCCACACTTCGATTGCCTG   
     
RS_628031  F1 TTTTTCGCATCTACCCCATGGCCA  T 190 bp 
  F2 TTTTTTTTTTTTTTTTTTTTTTCGCATCTACCCCATGTCCG  C 210 bp 
 R GACAAAGGTAGCACCTCATC   
     
RS_117474883  F1 ACCAACTTACCAGGTGAGATAAACATC G 280 bp 
 F2 AGCGGACACGCAGGACCGCCAACTTACCAGGTGAGATAAAGATG C 300 bp 
 R CTTCAGTCTCTGACTCATGCC   
     
RS_34205214  F1 AGACCTGTTCCGCACGCT A 400 bp 
 F2 TTTTTTTTTTTTTTTTTTTTAGACCTGTTCCGCACGCC G 420 bp 
 R CCACTGGTGATCTCCCAAAGG   
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Preliminary results obtained using each primer set in uniplex proved to be of better 
quality than the previously designed sets. Rigorous optimization was, however, 
required for each primer set to work optimally. In order to achieve this, the approach 
set out by Markoulatos et al. (2002) was followed. It prescribes that the amount of 
primer and reaction constituents be optimized first. Since the Qiagen Multiplex kit 
PCR buffer being used is sold pre-optimized, only the amount of primer could be 
further optimized. All primers were diluted to a working concentration of 4 µM. This 
would then result in a primer concentration of 0.4 µM in each reaction. To begin with, 
two primer sets were duplexed in a single reaction, each at 0.4 µM final primer 
concentration. The concentration of each primer set was carefully adjusted initially by 
decreasing the concentration to 0.2 µM for one primer set. When a consensus was 
reached, each primer set at 0.2 µM, a third primer set was introduced. The process 
then continued to incorporate a third and fourth primer set. This approach worked 
very well until the fourth primer set was added, and some drop out was observed. 
Some bands were no longer resolved on the gel. This finding was compounded when 
the fifth primer set was incorporated. Three bands were resolved, two of the bands 
from the triplex and the expected fifth primer set band. It was thus determined to be a 
result of secondary structures and dimmers forming between the primers in the 
multiplex. All secondary structures produced by the primers were re-analysed. 
Alignments were then drawn for each primer set and between primer sets. It was 
discovered that several of the primers were indeed forming dimers, each dimer having 
a greater binding-specificity than they would have with DNA. 
 
Therefore, it was necessary to run a gradient PCR to determine optimum annealing 
temperatures. Once completed, it became evident that the optimized annealing 
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temperatures had had no effect on the binding specificities of the primer sets. 
Persistently, an amplicon drop out was observed. As a result of the random tails 
attached to each primer, secondary structures and dimers had formed within the 
multiplexes and this was determined to be the primary factor affecting the binding 
specificity of the primers. 
 
In publications penned by Chun et al. 2007, Dixon et al. 2005 and Kenta et al. 2008, a 
similar technique to the PAMSA method is described. The methods described made 
use of the same allele-specific primer design as described by Gaudet et al, 2007, but 
used a multitude of additions to the primer tails instead of random bases for primer 
tails. These included poly (I) additions within the primer sequence (Chun et al, 2007), 
universal primer tails (Dixon et al, 2005) and dye-labelled allele specific primers 
(Kenta et al, 2008). Since it has been validated and is highly reliable for SNaPshot® 
genotyping, Poly (T)-tails were determined to be the best approach, as described by 
Nelson et al. (2007). This has prevented the formation of many hairpin loops and 
other secondary structures, provided that the primer itself did not have any A-runs. 
Furthermore, the primer sequences and the DNA sequence of interest could not be 
AT-rich as the primers would bind non-specifically and amplify the incorrect 
fragment of DNA. This method formed the basis of design for M2. Four of the five 
primer sets in M2 were designed to have 5‟ poly-T tails. This resulted in a much more 
stable and specific interaction between the primers and targets. Optimization for M2 
was virtually non-existent, barring the adjustment of the concentration of one primer 
set with a random base tail. Furthermore, the sizes of the amplified products remained 
similar, thus allowing primers to be exchanged between the two multiplexes. 
Therefore, two primer sets were exchanged between the two multiplexes. These 
 
 
 
 
 40 
consisted of primer sets 2282143 and 34305973 in M1, and primer sets 34205214 and 
35167514 in M2.  
 
A great improvement was obtained in the performance of the re-designed multiplexes. 
However, some optimization was still required as the annealing temperatures of the 
new primer sets were above that of the others. Immediately, this presented a new 
challenge. Non-specific amplification would be prevalent as a result of the difference 
in annealing temperature. To overcome this challenge, the concentration for those new 
primer sets was analysed. A concentration spectrum (Figure 2.2) was generated for 
each primer to determine the lowest possible concentration that could be used without 
sacrificing resolution quality. It was discovered that a final reaction concentration of 
0.2 µM presented the best possible results.  
 
 
Figure 2.2: Primer concentration gradient for primer set 3610 on 3% agarose gel. Lane M: 
Marker.  Lane 1: 0.5 µM primer. Lane 2: 0.4 µM primer. Lane 3: 0.3 µM primer. Lane 4: 0.2 µM 
primer concentration. Lane 4 presented the optimal concentration for this primer. Note, the non-
specific amplification is a result of the standard, non-optimized, annealing temperature used for 
amplification. 
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Moreover, this also allowed any primer set causing a loss of resolution to be 
exchanged for one from M2 without further optimization required. The resulting 
multiplexes (Table 2.3) were, therefore, significantly more specific and generated 
better results.  However, in order to reach such results it was through trial and error 
primer sets were exchanged until a perfect fit was achieved across all multiplexes.  
 
Table 2.2. Summary of final multiplex components 
 
         RsID        Polymorphism           Product Size 
M1   
34130495 G > A 50 – 70 bp 
35167514 A > Del 90 bp 
34104736 C > T 100 – 120 bp 
36103319 G > T 210 – 230 bp 
34205214 A > G 400 – 420 bp 
   
M2   
683369 G > C 70 – 90 bp 
628031 T > C 190 – 210 bp 
34305973 T > Del 250 bp 
117474883 G > C 280 – 300 bp 
2282143 C > T 320 – 340 bp 
 
This technique was then ready to be critically tested and evaluated in order to 
determine whether genotyping would be possible. The initial results showed a good 
potential. However, in order to properly resolve the target products on agarose gel the 
correct balance between the concentration of the gel and the size of the fragments 
needed to be established. Because each SNP site has one, or both, of two possible 
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fragment sizes, separated by a 10 – 20bp size difference it was necessary to determine 
at which voltage the fragment would correctly separate through the gel without  the 
smallest fragments running off the gel. It was thus determined, by sequentially 
increasing the concentration of the gel and voltage of the electrophoresis, that agarose 
gel of concentration of between 1.5% and 3%, and an electrophoresis voltage of 
between 60 and 75 volts, yielded the most suitable results. This allowed the smallest 
fragment to be clearly viewed without running off the gel as well as the larger 
fragments to separate out correctly. It was determined that an agarose gels 
concentration of 2% and electrophoresis voltage of 75 volts (7.5V.cm
-1
) was optimal 
and set as a standard.  
 
 
 
Figure 2.3: Multiplex one genotyping result on 2.5% agarose gel. Lane M: Marker. Lane 1: 
Negative control. Lane 2: 34205214, genotype GG. Lane 3: 35167514, genotype CC. Lane 4: 
36103319, genotype CC. Lane 5: 34130495, genotype AA. Lanes 6: 34104736, genotype AA. Lane 
7: Sample 38, genotype GCCAA.  
 
In M1 some non-specific amplification was observed (Figure 2.3). Primer set 
34205214 amplified a second band at 100 bp while primer set 34104736 amplified a 
second band at 80 bp. It is important to note that although this nonspecific 
amplification may be seen in Figure 2.3, the amplified products had no effect on the 
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efficacy of genotyping. The bands displayed were separate and settled between the 
bands of interest. Therefore, it may be said that further optimization will be required 
to generate sharper genotyping profiles. Multiplex 2 (Figure 2.4) did not display any 
non-specific amplification.  
 
 
 
Figure 2.4 Multiplex two genotyping result on 2.5% agarose gel. Lane M: Marker. Lane 1: 
683369, genotype GG. Lane 2: 2282143, genotype GG. Lane 3: 628031, genotype CC. Lane 4: 
34305973, genotype GG. Lane 5: 117474883, genotype GG. Lane 6: Sample 38, genotype 
GGCGG. Lane 7: Negative control.  
 
 
The development of this technique may be said to be of paramount importance not 
only specifically for its application presented herein but also for future work. This 
technique would be useful in a large host of applications and will form the basis of 
genotyping for future students and academics. It has been demonstrated to allow for 
large sample numbers, and SNP numbers, to be investigated in a relatively short 
amount of time with great accuracy and precision. Moreover, since it has been 
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optimized as a multiplex of five SNPs each, the cost incurred by use of this technique 
is minimal compared with many similarly accurate methods. Developing this 
technique has therefore become crucial in the expansion and advancement of a 
laboratory which cannot afford expensive equipment and which has a minor annual 
budget.  
 
2.3.2. Validation of MAS-PCR Technique 
Validation plays a fundamental role in determining the reliability and limitations of 
novel techniques. It is important to determine if the analytical procedure is adequate 
for its intended use (Butler et al, 2004). The technique as describe above was 
validated using SNaPshot® mini-sequencing. The genotypes for 10 samples, 
generated from MAS-PCR (Figure 2.5), were compared with those generated by 
SNaPshot® mini-sequencing (Figure 2.6). Sample 38 was chosen as reference and 
genotyped with both MAS-PCR and SNaPshot®. The results obtained were a perfect 
match. 
The SNaPshot® technique, being more specific, did, however, resolve and confirm 
those genotypes which were harder to determine from the gel (Data not shown).  
 
 
Figure 2.5: Multiplex one genotyping result on 1.8% agarose gel. Lane M: Marker. Lane 1: 
34205214, genotype GG. Lane 2: 35167514, genotype CC. Lane 3: 36103319, genotype GG. Lane 
4: 34130495, genotype AA. Lane 5: 34104736, genotype AA. Lane 6: Sample 38, genotype 
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GGCAA. Lane 7: Sample 23 genotype GCCAA. Lane 8: Sample 5, genotype GCCAA. Lane 9: 
Sample 64, genotype GCCAA. Lane 10: Sample 33, genotype GCCAA. Lane 11: Sample 80, 
genotype GCCAA. Lane 12: Negative control.  
 
 
Figure 2.6: SNaPshot®  validation of the SNPs genotyped by MAS-PCR using Sample 38 as the 
reference sample. As a result of the variability of the electroconductivity of SNaPshot®  extended 
sequences, an amount of drift is observed within the samples. Thus, smaller fragments tend to 
drift by up to 20bp from their expected size. 
 
 
2.3.3. Blind Tests 
To confirm and validate the multiplex system developed, an intralaboratory blind test 
was performed as determined by Yang et al. (2004). The exact PCR conditions and 
set up was used for the blind test. However, in order to test the efficacy of the 
multiplex developed, a representative number of samples were chosen at random 
(10% of the total). These samples were then shuffled so as to further randomise the 
test. After gel electrophoresis the exact sample had to be identified, from a known 
420bp
p 
230bp
p 120bp
p 90bp
p 70bp
p 
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consignment of sample IDs, using only the genotype generated (Figures 2.7 and 2.8 
respectively).   
 
Figure 2.7: Genotyping results for multiplex 1 used for the blind test. A 2% agarose gel was used. 
Lane M: Marker. Lane 1: Sample 7, genotype G*CAA. Lane 2: Sample 9, genotype GGCAA. 
Lane 3: Sample 3, genotype *GCAG. Lane 4: Sample 10, genotype **CAA. Lane 5: Sample 1, 
genotype GGCAG. Lane 6: Sample 8, genotype GGCAG. Lane 7: Sample 2, genotype GGCAG. 
Lane 8: Sample 6, genotype G*CAA. Lane 9: Sample 5, genotype *GCAA. Lane 10: Sample 4, 
genotype GGCAA. Lane 11: negative control. (* indicates missing allele) 
 
 
It is important to note that all SNP loci in M2 are homozygous (Figure 2.8). Therefore 
some amplicons might appear too close to the next. However, this has no effect on 
genotyping since only one allele is present. More time for separation would increase 
the discriminative ability of the gel. 
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Figure 2.8: Genotyping result for Multiplex 2. A 2% agarose gel was used. Lane M: Marker. 
Lane 1: Sample 7, genotype CGTCG. Lane 2: Sample 9, genotype CCTCG. Lane 3: Sample 3, 
genotype CCTCG. Lane 4: Sample 10, genotype CCTCG. Lane 5: Sample 1, genotype CCTCG. 
Lane 6: Sample 8, genotype CCTCG. Lane 7: Sample 2, genotype CCTCG. Lane 8: Sample 6, 
genotype CGTCG. Lane 9: Sample 5, genotype CCTCG. Lane 10: Sample 4, genotype CCTCG. 
Lane 11: negative control. 
 
 
The initial blind test results (Table 2.4) showed that five samples in M1 exhibited 
incomplete genotypes, which was as result of the improper amplification and 
electrophoresis conditions. However, after performing the blind test again, 100% of 
the tested samples were correctly identified thus confirming the validity of the 
multiplex PCR system presented herein.  
 
Table 2.3. Result of the 10 sample blind test 
Sample ID Identities of samples Pass / Fail 
1 Identified sample 7 Pass* 
2 Identified sample 9 Pass 
3 Identified sample 3 Pass* 
4 Identified sample 10 Pass* 
5 Identified sample 1 Pass 
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6 Identified sample 8 Pass 
7 Identified sample 2 Pass 
8 Identified sample 6 Pass* 
9 Identified sample 5 Pass* 
10 Identified sample 4 Pass 
Where * indicates incomplete genotypes and therefore unidentified samples. 
 
 
 
2.4. Summary 
To summarise briefly, the technique presented herein does provide a reliable means 
for genotyping large quantities of samples relatively quickly. Not only is this 
technique well suited to laboratories with modest budgets, but it is also well designed 
and has been proven to be highly effective and efficient. The data generated was 
sufficient for genotyping and proven to be accurate. The assay is, therefore, both cost-
effective while remaining reliable and fairly easily implemented. With exceptionally 
modest effort this technique can be further adapted for more extensive forms of assays 
and research interests.  
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Chapter Three 
 
Analysis of Twenty SLC22A1 Genetic Variants within the 
Cape Coloured Population 
3.1. Introduction  
The Cape Coloured population of South Africa, also called the Cape Mixed Ancestry 
population or the Cape admixed population, is a result of contributions from Asian 
and European immigrants as well as indigenous populations (Abrahams et al, 2010). 
This is advantageous as the mixed ancestries of this populations allows for the 
identification of genetic risk factors (Smith et al, 2001; Tian et al, 2007) and may 
provide the intrinsic variability needed to untangle complex gene-environment 
interactions which may help explain the population differences in the epidemiology of 
complex disease (Via et al, 2009). The aim of this part of the study was therefore to 
investigate the genetic diversity of the SLC22A1 gene within the Cape Coloured 
population. A novel SNaPshot® assay was specifically developed to investigate 20 
SNP variations on the SLC22A1 within this population. The SNaPshot® assay, a 
genotyping technique based on conventional PCR, is a high-throughput method, 
which requires little more than well-designed primers. It is also less time-consuming 
and relatively rapid while remaining robust and accurate.  
 
This chapter describes the development and implementation of a SNaPshot® assay as 
a high-throughput method for genotyping and generating population genetics data for 
the Organic Cation Transporter 1 gene within the Cape Coloured population. It also 
presents the statistical analysis of the results including main population genetics 
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parameters. This was followed by a discussion of possible pharmacogenetic 
implications of the obtained results for this uniquely admixed population from South 
Africa. 
 
3.2. Materials and Methods 
3.2.1. Sample Collection 
Sample collection was performed as previously described in Chapter Two. 
 
3.2.2. DNA Extraction 
DNA extractions were performed as previously described in Chapter Two. 
 
3.2.3. SNP Selection 
Previously reported SNP variants on the SLC22A1 gene were selected from the 
Pharmacogenomics Knowledgebase (http://www.pharmgkb.org), the UCSF-PMT 
(http://www.pharmacogenetics.ucsf.edu/) database and the NCBI-SNP database. 
Among the 20 SNPs selected for this study, 9 variants were annotated and have been 
shown to have clinical relevance, and the remaining SNPs are still under 
investigation.  
 
3.2.5. Primer Design 
All primers were designed using the online software BatchPrimer 3 
(http://probes.pw.usda.gov/cgi-bin/batchprimer3/batchprimer3.cgi), Primo 
(http://www.changbioscience.com/primo) and PrimoSNP 
(http://www.changbioscience.com/primo/primosnp.html). Primers were designed to 
genotype the selected SNPs in two multiplexes (MplexI and MplexII), each covering 
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10 SNPs, according to the method described by Nelson et al. (2007). The primers 
were used for the PCR amplification and the SNaPshot® mini-sequencing reactions. 
 
3.2.6. PCR Amplification 
PCR amplification was performed as previously described in Chapter Two with a 
minor difference in cycling conditions. The primers used for the PCR amplification 
for the two multiplexes are listed in Table 3.1.  PCR amplifications were performed 
on a GeneAmp 2700/ 2720 (Applied Biosystems) thermal cycler. Thermocycling 
conditions were as follows; 95°C for 15 min, 94°C for 30 s, 60°C for 90 s, 72°C for 
90 s, for a total of 40 cycles, followed by 72°C for 10 min and a final hold at 4°C. 
PCR products were then verified by agarose gel electrophoresis. An aliquot of 3 µl of 
each product was run on a 2% agarose gel at 10V.cm
-1
. The gel was then stained with 
0.1 µg.ml
-1
 Ethidium Bromide and visualised under UV light. 
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Table 3.1.  List of PCR amplification and extension primer sequences for Multiplex 1 
SNP ID Primer Sequence Concentration Polymorphism Extension Primer Sequence Size (bp) 
Rs_36103319 F-CTGGTCAGCAAGGGCAAC 0.2 µM C > A 5-Poly-T-GGGCAACTGGATGGCTG -F 23 
  R-GGCCTCATCCCCATGATAA       
Rs_12208357 F-CTGACCACCACTGCCAGAGT 0.2 µM A > G 10-Poly-T-GGGCTCCAGCCACAGC -F 26 
 R-CCTGGCACTGTATAGTTCAGCTC     
Rs_1867351 F-CAGGCCTGGCACTGTTAGTT 0.2 µM G > A 15-Poly-T-GCTCAGCCACCCCAGG -F    32 
 R-TTCACACCTGACCACCACTG     
Rs_34104736 F-TTTGGCCGTAAGCTGTGTCT 0.2 µM G > A 20-Poly-T-GCCATGAGCACGCCC -R 36 
 R-CATGTAGTTGGGCGAGAAGG     
Rs_2282143 F-AAAGCTGAGCCCTTCATTTG 0.2 µM A > G 25-Poly-T-GACCTGTTCCGCACGC -F 42 
 R-CCCCTCACCACAGGTACATC     
Rs_34130495 F-GCCTTCATAGCCCTCATCAC 0.2 µM C > T 30-Poly-T-CACCATTGACCGCGTG -R 47 
 R-CCGCCAACAAATTTGACAT     
Rs_16891138 F-GGGCCACAGGCTGTAGTTTG 0.2 µM T > G 35-poly-T-AGGTGCCCGAGGGTTC -F 52 
 R-AACATCTCTCTCAGGTGCCCG     
Rs_35167514 F-TGGCCATGTCAAATTTGTTG 0.2 µM T > - 40-Pol-T-GCAGCCTGCCTCGTC -R 55 
 R-TGATGAAAGCAGACAACTTACCA     
Rs_2297373 F-ATCTGTGTGGGCATCGTCTT 0.2 µM G > C 50-Poly-T-GGTCAGGTGTGAAACCCAG -R 69 
 R-CAGGACTCTGGCAGTGGTG     
Rs_34305973 F-TGGCCATGTCAAATTTGTTG 0.2 µM G > - 45-Poly-T-CAACTTACCAGGTGAGATAAAAATC -F 70 
 R-TGATGAAAGCAGACAACTTACCA     
All extension primers were used at a final concentration of 0.2 µM
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Table 3.2. List of PCR amplification and extension primer sequences for Multiplex 2 
SNP ID Primer Sequence Concentration Polymorphism Extension Primer Sequence 
Size 
(bp) 
RS683369  GACTCCTGGAAGCTGGACCT 0.2 µM G > C 5-poly-T-CAACACCGAGAGAGCCAAA -F 24 
 GTAGCCAACACCGAGAGAGC     
RS628031  AGCCCTCATCACCATTGACCG 0.2 µM T > C 10-Poly-T-CCGCATCTACCCCATGGCC -F 29 
 AATCATGACGAGGCAGGCTGC     
MPJ6_O1004  CTCAGCTGTGTAGACCCCCT 0.2 µM G > A 15-Poly-T-CACCAACAGGAGCCACCTGC -F 35 
 CGTGTCATACACCCAGCCATC      
RS34205214  CACCGAAAAGCTGAGCCCTTC 0.2 µM A > G 20-Poly-T-ATGAAGGTGCGCTTCCTCAGG -F 41 
 CCCCTCACCACAGGTACATC     
RS117474883  TGGCCATGTCAAATTTGTTG  0.2 µM G > C 25-Pol-T-ATTTTTATCTCACCTGGTAAGTTGGTAAG -F 54 
 ATTGCCTGGGAAATGATGAA     
RS35191146  GTCAAATTTGTTGGCGGGGGC  0.2 µM G > - 30-Poly-T-ACCAACTTACCAGGTGAGATAAAAAT -R 56 
 TCCCCACACTTCGATTGCCTG      
RS34059508  TCTGAGGTGCTGAGCACTGGA 0.2 µM G > A 35-Poly-T-GGGAGGAACACACCATCACTC -R 61 
 AATGAGGGGCAAGGCTTGCCA     
RS115733275  CTCAGGATCACCTGGATTCCT 0.2 µM G > T 40-Poly-T-CACAGGGTCCTGGTGGAAC -R 66 
 CTGCTTCATCACGAGAACCAC     
RS116824962  CAGTGAGGGAAAGGCAAGACA 0.2 µM C > T 45-Poly-T-CCAGGCATGGTGGCTAA -F 71 
 GGTCTCGAACTCCTGGCTTCA     
RS118060798  TGATTTAGCTAGGCCTCGGGT 0.4 µM A > G 50-Poly-T-GGGTGTGCAGTGAATGGAA -F 79 
  TTCCAACCGCACCATGGCATT        
All extension primers were used at a final concentration of 0.2 µM, 
 
 
 
 
 54 
3.2.7. Post PCR Purification 
Subsequent to verification, the PCR products were purified using SAP (Amersham) 
and Exo I (USB, Cleveland, OH, USA). 2 U SAP was added and 21 U Exo I was 
added to 5 µl PCR product, according to the manufacturer‟s instructions. Each 
product was then incubated at 37°C for 60 min followed by 15min inactivation at 
75°C. 
 
3.2.8. SNaPshot® Extension 
Primers used for single-base extension for Multiplex 1and 2 are listed in table 3.1 and 
3.2. All extension primers were synthesised by Integrated DNA Technologies 
Munich, Germany. The mini-sequencing reactions were performed in a final volume 
of 10 μl. Each reaction tube contained 2 μl SNaPshot® ready mix (Applied 
Biosystems), 3 μl purified PCR product, 0.4 μM primer mix and 3.5 μl water was 
added. A negative and positive control was supplied in the mini-sequencing reaction 
and was used according to manufacturer‟s instructions. The samples were then loaded 
onto a GeneAmp 2700 thermal cycler (Applied Biosystems) for the mini cycle 
sequencing reaction. Cycling conditions were as follows: 25 cycles of 96°C for 10 s, 
50°C for 5 s and 60°C for 30 s, followed by a 4°C hold. 
 
3.2.9. Post Extension Purification 
Subsequent to extension, the products were purified using SAP (Amersham). To each 
tube, 2 U SAP was added according to the manufacturer‟s instructions. Incubation at 
37°C for 60 min followed by 15min inactivation at 75°C then followed. 
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3.2.10. Detection and Data Analysis  
Amplicons were analysed on ABI Prism 3500 DNA sequencer.  A master mix was set 
up containing 7.5 μl HiDi Formamide (Applied Biosystems) and 0.5 μl GeneScan Liz 
120 (Applied Biosystems) size standard. Reactions were set up on 96-well plate 
supplied by Applied Biosystems. To each well a volume of 8 μl master mix was 
added together with 2 μl SAP-treated extension product. The plate was then 
centrifuged for 1 min at 3500 rpm and incubated at 95°C for 5 min, in a thermal 
cycler, to initiate DNA denaturation. Thereafter, the plate was loaded into the ABI 
sequencer (Applied Biosystems). The raw data generated was then analysed using 
Geneapper v4.1. software (Applied Biosystems). 
 
3.2.10. Statistical Analysis 
The statistical analysis of the data was performed using freely available software, 
including Haploview and Microsoft Excel applications GenAlEx 6.4.1 and SNPTools. 
GenAlEx, described by Peakall and Smouse (2006), is an in-MS-Excel application 
allows for various statistical analyses to be calculated and was the primary tool used 
for all statistical analyses. GeneAlEx was used to calculate allele frequency, the Hard-
Weinberg Equilibrium and the Shannon and Fixation indices. GenePop-on-the-web 
was used to calculate the G Exact Test to compare genotypic differentiation between 
the Cape Coloured and other global populations. SNPTools was used to convert 
genotypic data to haploview format. SNPTools (Chen et al, 2009) is also an MS-Excel 
application which allows raw data to be converted into a format suitable for various 
population genetics software, including Haploview, PLINK, Phase and SNPHAP. 
Haploview was then used to determine linkage disequilibrium between the 20 SNPs 
of the SLC22A1 gene within the Cape Coloured population.  
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3.3. Results and Discussion 
3.3.1. SNaPshot® Optimization and Genotyping 
The SNaPshot® genotyping assay is one of the most accurate, efficient and rapid 
methods available for high throughput genotyping. It is highly consistent, 
reproducible and more flexible than many other systems (Quintans, et al, 2004). In 
addition, this technique also has the advantage of requiring very few optimization 
steps. For the two multiplexes developed for this study, minor optimization was 
required for one SNP in the PCR amplification step. The concentration of this primer 
pair was increased to 0.4 µM as a result poor amplification. Once increased, enough 
template DNA was amplified for the mini-sequencing reaction. Thereafter, good 
profiles were generated for each primer set.  
 
 
Figure 3.1: Typical Multiplex 1 electropherogram. Note a shift of 12bp and 20bp in SNP1 and 
SNP3 respectively. 
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Figure 3.2: Multiplex 2 electropherogram. A large peak at position 58 to 65 for the A base was 
observed.  
 
A certain amount of drift is common for fragments during capillary electrophoresis. 
This is as a result of the length, sequence and dyes used to label the ddNTPs. 
Subsequently, the electrochemical nature of the extension products is slightly altered 
and the fragment migrates further than its determined size (Quintans, et al, 2004). 
Typically smaller fragments will experience a greater amount of drift than others 
(Quintans, et al, 2004). However, as a result of the fragment drift, and the sensitivity 
of the ABI 3500 Genetic Analyser, some confusion became evident when attempting 
to call the genotypes. Some fragment had migrated to form clusters of peaks (Figure 
3.1).  Therefore, it was decided that the two multiplexes should be split into four by 
selecting and combining every alternate primer set for a total of 5 SNPs per multiplex. 
This yielded more accurate results and allowed for more accurate genotyping.  
 
 
 
 
 58 
Table 3.3. Minor allele frequencies (MAF) of single nucleotide polymorphisms in Cape Coloured (C), African American (AA), Caucasian American (CA), Asian 
(A), Mexican (ME), Pacific Islander (P) and Sub-Saharan African (SSA). Minor allele frequencies for populations other than the Cape Coloured population were 
taken from the Pharmacogenomics Knowledgebase (http://www.pharmgkb.org), the UCSF-PMT (http://www.pharmacogenetics.ucsf.edu/) database and the NCBI-
SNP database (http://www.ncbi.nlm.nih.gov)       
RS ID 
Short 
ID 
Minor 
Polymorphism Genotype 
Population Group 
Allele            C          AA          CA           A         ME           P 
                      
n 100 198 200 60 20 14 
RS36103319 SNP1 T G > T G/G 96 98 100 30 10 7 
G/T 0 1 0 0 0 0 
T/T 4 0 0 0 0 0 
  0.020 0.005 0 0 0 0 
                  
n 100 198 194 60 18 14 
RS12208357 SNP2 C T > C T/T 50 99 83 30 8 7 
T/C 0 0 14 0 1 0 
C/C 0 0 0 0 0 0 
  0 0 0.072 0 0.056 0 
                  
n 100 198 194 60 18 14 
RS1867351 SNP3 C T > C T/T 68 56 61 9 4 4 
T/C 28 34 32 16 5 2 
C/C 4 9 4 5 0 1 
  0.180 0.263 0.206 0.433 0.278 0.286 
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Table 3.3 Continued 
RS ID 
Short 
ID 
Minor 
Polymorphism Genotype 
Population Group 
Allele    C         AA        CA           A         ME            P 
                      
n 100 198 200 60 20 14 
RS34104736 SNP4 T C > T C/C 85 99 99 30 10 7 
C/T 1 0 1 0 0 0 
T/T 14 0 0 0 0 0 
  0.145 0 0.005 0 0 0 
                      
RS2282143 SNP5 T C > T 
n 100 196 200 60 20 14 
C/C 84 82 100 25 10 7 
C/T 15 16 0 5 0 0 
        T/T 1 0 0 1 0 0 
  0.085 0.082 0 0.117 0 0 
              
n 100 136 184 42 14 14 
RS34130495 SNP6 A G >A G/G 50 67 92 21 7 7 
G/A 0 1 0 0 0 0 
A/A 0 0 0 0 0 0 
      0 0.007 0.011 0 0 0 
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Table 3.3 Continued 
RS ID 
Short 
ID 
Minor 
Polymorphism Genotype 
Population Group 
Allele            C          AA          CA            A         ME             P 
                      
n 100 200 198 60 20 14 
RS16891138 SNP7 C A > C A/A 50 93 99 30 10 7 
A/C 0 7 0 0 0 0 
C/C 0 0 0 0 0 0 
  0 0.035 0 0 0 0 
                  
n 100 136 184 42 14 14 
A/A 50 64 60 21 5 7 
RS35167514 SNP8 Del A > Del A/- 0 4 30 0 1 0 
-/- 0 0 2 0 1 0 
  0 0.029 0.185 0 0.214 0 
                  
n 100 136 184 42 14 14 
T/T 74 64 60 21 5 7 
RS34305973 SNP9 Del T > Del T/- 0 4 30 0 1 0 
-/- 26 0 2 0 1 0 
  0.130 0.029 0.185 0 0.214 0 
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Table 3.3 Continued 
RS ID 
Short 
ID 
Minor 
Polymorphism Genotype 
Population Group 
Allele            C          AA          CA            A         ME            P 
                      
n 100 200 200 60 20 14 
C/C 73 71 77 27 9 7 
RS2297374 SNP10 T C > T C/G 2 16 16 1 1 0 
G/G 25 13 7 2 0 0 
  0.260 0.21 0.15 0.083 0.05 0 
                  
n 100 200 200 60 20 14 
C/C 12 99 88 29 9 7 
RS683369 SNP11 G C > G C/G 0 1 11 1 1 0 
G/G 88 0 1 0 0 0 
  0.870 0.005 0.065 0.017 0.05 0 
                  
n 100 136 184 32 14 14 
G/G 40 4 15 2 0 0 
RS628031 SNP12 A G > A G/A 49 28 44 6 3 1 
A/A 11 36 33 13 4 6 
  0.360 0.735 0.598 0.762 0.786 0.929 
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Table 3.3 Continued 
RS ID 
Short 
ID 
Minor 
Polymorphism Genotype 
Population Group 
Allele            C         AA          CA            A         ME             P 
                      
n 100 - - - - - 
G/G 75 - - - - - 
MPJ6_OC1004
a
 SNP13 A G > A G/A 24 - - - - - 
A/A 1 - - - - - 
  0.130 - - - - - 
                  
n 100 196 200 60 20 14 
G/G 50 93 100 30 10 7 
RS34205214 SNP14 A G > A  
G/A 0 4 0 0 0 0 
    A/A 0 1 0 0 0 0 
      0 0.031 0 0 0 0 
    n 100 - - - - - 
G/G 0 - - - - - 
RS117474883 SNP15 C G > C G/C 0 - - - - - 
C/C 50 - - - - - 
  1 - - - - - 
 
 
 
 
 63 
 
Table 3.3 Continued 
RS ID 
Short 
ID 
Minor 
Polymorphism Genotype 
Population Group 
Allele            C          AA          CA            A         ME            P 
        n 100 136 184 42 14 14 
G/G 70 64 60 21 5 7 
RS35191146 SNP16 Del G > Del G/- 30 4 30 0 1 0 
-/- 0 0 2 0 1 0 
  0.155 0.029 0.185 0 0.214 0 
                  
n 100 200 200 60 20 14 
RS34059508 SNP17 A G > A G/G 50 100 92 30 10 7 
G/A 0 0 8 0 0 0 
A/A 0 0 0 0 0 0 
  0 0 0.04 0 0 0 
                  
n 100 - - - - - 
G/G 0 - - - - - 
RS115733275 SNP18 T G > T G/T 0 - - - - - 
T/T 50 - - - - - 
  1 - - - - - 
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Table 3.3 Continued 
RS ID 
Short 
ID 
Minor 
Polymorphism Genotype 
Population Group 
Allele           C        AA        CA        A      ME       P 
        n 100 - - - - - 
C/C 50 - - - - - 
RS116824962 SNP19 T C > T C/T 0 - - - - - 
T/T 0 - - - - - 
  0 - - - - - 
                  
    n 100 - - - - - 
A/A 50 - - - - - 
RS118060798 SNP20 G A > G A/G 0 - - - - - 
G/G 0 - - - - - 
  0 - - - - - 
Zero (0) indicates a value of zero.  
Dashes (-) indicate absence of published data. 
Minor alleles and minor allele frequencies for other populations were determined from the 1000Genome reference data.   
a
: SNP 13 (MPJ6_OC1004) has been characterised by Itoda et al. 2004, only in the Japanese population. Minor allele frequency: 0.004. 
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3.3.2. Statistical Parameters 
Statistical analysis plays an important role in population genetics as it allows 
population data to be summarized in a clear and concise format (Figure 3.3) (Mailloux 
and LaBerge, 2010). Population genetics data obtained for the investigated SNPs were 
analysed using various statistical analysis software to calculate important parameters, 
and possible pharmacogenetics implications were then discussed. GeneAlEx was used 
to calculate allele frequency, the Hardy-Weinberg Equilibrium and the Shannon and 
Fixation indices. GenePop-on-the-web was used to calculate the G Exact Test to 
compare genotypic differentiation between the Cape Coloured and other global 
populations. Haploview was used to determine linkage disequilibrium between the 20 
SNPs of the SLC22A1 gene within the Cape Coloured population.  
 
In Table 3.4 an assortment of figures and indices are given. Shannon‟s index (I) is a 
measure of the differentiation across the loci. However, no values can be calculated 
for any monomorphic loci. The value calculated in the table specified above, is 
indicative of the difference in allele frequency, where a large difference in the 
frequency of each allele at a locus is given by a low value. If the allele frequencies are 
more evenly distributed, at the specific locus, then the Shannon Index approaches 1. 
Only two of the variants displayed such extreme difference between the allele 
frequencies. SNP15 and SNP18 both exhibited allele frequencies of above 95% for 
the minor allele. This is indicative of a large variation when compared with the 
expected ancestral allele. It is suggested that the results produced here additionally 
indicate that the minor allele frequency far outweighs the major frequency.  
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Figure 3.3: Minor allele frequencies across various populations. A: Multiplex 1 data. B: Multiplex 2 data. C – Cape Coloured, AA – African American, CA – 
Caucasian American, A – Asian, ME – Mexican, P – Pacific Islander, SSA – Sub-Saharan African. 
 
 
 
 
 67 
 
 
 
 
Table 3.4. Summary of Heterozygosity and Fixation Indices generated using GenAlEx 
Population Locus N Na Ne I Ho He UHe F  
Cape Coloured           
 rs36103319 100 2.000 1.041 0.098 0.040 0.039 0.039 -0.020  
 rs12208357 100 1.000 1.000 0.000 0.000 0.000 0.000 #N/A  
 rs1867351 100 2.000 1.419 0.471 0.280 0.295 0.297 0.051  
 rs34104736 100 2.000 1.330 0.414 0.010 0.248 0.249 0.960  
 rs2282143 100 2.000 1.184 0.291 0.150 0.156 0.156 0.036  
 rs34130495 100 1.000 1.000 0.000 0.000 0.000 0.000 #N/A  
 rs16891138 100 1.000 1.000 0.000 0.000 0.000 0.000 #N/A  
 rs35167514 100 1.000 1.000 0.000 0.000 0.000 0.000 #N/A  
 rs34305973 100 2.000 1.292 0.386 0.260 0.226 0.227 -0.149  
 rs2297374 100 2.000 1.625 0.573 0.020 0.385 0.387 0.948  
 rs683369 100 2.000 1.292 0.386 0.020 0.226 0.227 0.912  
 rs628031 100 3.000 1.877 0.683 0.500 0.467 0.469 -0.070  
 MPJ6_O1004 100 2.000 1.292 0.386 0.240 0.226 0.227 -0.061  
 rs34205214 100 1.000 1.000 0.000 0.000 0.000 0.000 #N/A  
 rs117474883 100 1.000 1.000 0.000 0.000 0.000 0.000 #N/A  
 rs35191146 100 2.000 1.355 0.431 0.290 0.262 0.263 -0.107  
 rs34059508 100 1.000 1.000 0.000 0.000 0.000 0.000 #N/A  
 rs115733275 100 1.000 1.000 0.000 0.000 0.000 0.000 #N/A  
 rs116824962 100 1.000 1.000 0.000 0.000 0.000 0.000 #N/A  
 rs118060798 100 1.000 1.000 0.000 0.000 0.000 0.000 #N/A  
           
Population   N Na Ne I Ho He UHe  
Cape Coloured  Mean 100.000 1.550 1.185 0.206 0.091 0.127 0.127  
  SE 0.000 0.135 0.056 0.053 0.032 0.034 0.034  
Where: Na = No. of Different Alleles, Ne = No. of Effective Alleles = 1 / (Sum pi^2), I = Shannon's 
Information Index = -1* Sum (pi * Ln (pi)), Ho = Observed Heterozygosity = No. of Hets / N, He 
= Expected Heterozygosity = 1 - Sum pi^2, UHe = Unbiased Expected Heterozygosity = (2N / (2N-
1)) * He, F = Fixation Index = (He - Ho) / He = 1 - (Ho / He), Where pi is the frequency of the nth 
allele for the population & Sum pi^2 is the sum of the squared population allele frequencies. 
 
 
The Fixation index, also called the Inbreeding Coefficient, is a function of the 
heterozygosity of a locus. The indices shown here suggest that for some SNPs, SNP2, 
SNP6, SNP7, SNP8, SNP14, SNP15, SNP17, SNP18, SNP19 and SNP20, the 
population is indeed separate from others. However, this may also indicate that these 
SNPs are always inherited in the same manner in all populations and would, therefore, 
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not display any sort of genetic polymorphism. These indices also indicate that a large 
amount of inbreeding has occurred in this population. It may therefore be said that this 
population rarely interbreeds with other populations.  
 
The expected and observed genotype frequencies are determined according to the 
Hardy-Weinberg principle (Table 3.5). The difference in observed and expected 
genotypes is indicative of the amount of external selective pressure applied by 
mutation, mating and random genetic drift. None of the loci showed an inclination 
toward the expected results determined by the Hardy-Weinberg principle. According 
to the HWE principle, a significant amount of mutation has occurred within the study 
samples. Although the observed genotypes, for most samples, conform to the standard 
set by the expected genotypes the actual weight for each genotype is far greater than 
expected. Therefore, with the exception of three SNPs (4, 10 and 11) the majority of 
SNPs were determined to be in HWE (Appendix II).  
 
However, SNP4, SNP10 and SNP11 displayed very low or no amount of 
heterozygosity. SNP10 displayed an observed heterozygosity value of 0.010, which 
equates to 2% of the subject population. For the remaining SNPs (10 and 11), 
individuals were homozygous for either the minor or major allele. These results may 
be said to be the cause of them being designated as significant as neither case, very 
low heterozygosity and homozygosity, fits the Hardy-Weinberg model. 
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Table 3.5. Hardy-Weinberg Chi-Square test  
Locus DF ChiSq Prob Signif 
rs36103319 1 0.042 0.838 ns 
rs12208357 Monomorphic   
rs1867351 1 0.265 0.607 ns 
rs34104736 1 92.097 0.000 *** 
rs2282143 1 0.127 0.721 ns 
rs34130495 Monomorphic   
rs16891138 Monomorphic   
rs35167514 Monomorphic   
rs34305973 1 2.233 0.135 ns 
rs2297374 1 89.875 0.000 *** 
rs683369 1 83.098 0.000 *** 
rs628031 2 2.350 0.503 ns 
MPJ6_O1004 1 0.372 0.542 ns 
rs34205214 Monomorphic   
rs117474883 Monomorphic   
rs35191146 1 1.147 0.284 ns 
rs34059508 Monomorphic   
rs115733275 Monomorphic   
rs116824962 Monomorphic   
rs118060798 Monomorphic   
Where DF indicates the amount of the number of alleles other than the ancestral allele and *** 
indicates P<0.001 
 
 
 
Interestingly, SNP11 remained a constant feature in the statistical analyses presented. 
Under the Shannon and Fixation indices, this SNP was found to have high statistical 
significance. However, this may be due to the high amount of individuals 
homozygous for the minor allele. It may be suggested that this SNP will have to be 
screened against other populations to determine if it is always inherited in the same 
manner or if this population is completely separate from others, with regard to this 
SNP. In table 3.6 the SNPs are compared between populations to highlight the 
similarity between these populations. SNP4 and SNP11 are shown to be completely 
different from all populations. This would suggest that, in relation to these SNPs, the 
Cape Coloured population is indeed separate from all other populations screened.   
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Table 3.6. Population differentiation between Cape Coloured and global populations. Significant data is shown only. All monomorphic or absent data has been 
removed. Where C – Cape Coloured, CA - Caucasian American, AA – African American, A – Asian, ME – Mexican and P – Pacific Islander 
  SNP ID SNP1 SNP2 SNP3 SNP4 SNP5 SNP6 SNP7 SNP8 SNP9 SNP10 
Population  
Comparison           
 CA & C   0.36892   0.01281   1.00000   0 0.00005   0.49770   0.01354   N/A N/A 0.04704   
 
AA & 
C   0.12294   N/A 
0.05089   
0 1.00000   1.00000   N/A N/A N/A 0.43133   
 
A    & 
C  0.12141   N/A 0 0 0.43272   N/A N/A N/A N/A 0.00051   
 
ME & 
C 0.12081   1.00000   0 0 0 N/A N/A N/A N/A 0 
  
P     & 
C  0.11981   N/A 0 0 0 N/A N/A N/A N/A 0 
 
  SNP ID SNP11 SNP12 SNP13 SNP14 SNP15 SNP16 SNP17 SNP18 SNP19 SNP20 
Population 
Comparison           
 
CA & 
C   0 0.47494   N/A N/A N/A N/A 0.00626   N/A N/A N/A 
 
AA & 
C   0 0.03446   N/A 0.05774   N/A N/A N/A N/A N/A N/A 
 
A    & 
C  0 0.00625   N/A N/A N/A N/A N/A N/A N/A N/A 
 
ME & 
C 0 0.00073   N/A N/A N/A N/A N/A N/A N/A N/A 
  
P     & 
C  0 0 N/A N/A N/A N/A N/A N/A N/A N/A 
Where N/A indicates no published data present.
 
 
 
 
 71 
SNPTools was used to convert the raw data to a format acceptable for use with 
Haploview. Although SNPTools incorporates various statistical functions, GenAlEx 
was found to be more beneficial for complex analyses. Once converted into 
Haploview format, a Linkage-disequilibrium (LD) map could then be generated. 
Several approaches for viewing the data may be harnessed using the software. As a 
default, LD maps are displayed under the standard D‟ colour scheme. Diagonal lines 
represent different SNPs while the boxes represent the pairwise comparison between 
two SNPs (Figure 3.4). This scheme arranges the linkage between SNPs based on a 
scoring system designed to make use of the Log of Odds Ratio (LOD) and D-prime 
(D‟) value for each SNP combination (Barrett et al, 2005). 
 
 
Figure 3.4: LD map of the genotype frequencies for all 20 SNPs. Gaps are seen as a result of the 
presence of homozygous samples. 
 
 
Refining the input data to include only those SNPs which are heterozygous, a more 
accurate depiction of the LD is produced (Figure 3.5).  
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Figure 3.5: LD map of the 10 heterozygous SNP markers.  
 
 
In Figure 3.5, 2 pairwise comparisons, blocks 62 and 42, display an amount of LD. 
The block labelled 42, a pairwise comparison between SNP 11 and SNP 12, has a D‟ 
value of 0.422 and LOD of 2.53 thus indicating minor LD. The same can be said for 
block 62, comparison between SNP11 and SNP4.  However, because the D‟ value is 
0.62 and the LOD score is 0.76, the LD exhibited by this block is even weaker than 
the aforementioned block (block 42). Therefore, the degree of LD that existed 
between these comparisons can be said to be of minor significance as an LOD score 
of 3 is considered evidence for linkage. As described above, the blue block indicate 
perfect LD scores, however, they are not statistically significant.  
 
Under a different setting (Figure 3.6), the same data can be analysed in a more simple 
fashion. The map generated displays the data based on the confidence bounds set by 
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the user. This method is also reliant on the D‟ values for each pairwise comparison 
but does not take the LOD score into account. Dark Grey squares indicate strong 
evidence of LD while white squares are indicative of a strong existence of 
recombination. Light grey squares (not seen here) are deemed uninformative. Figure 
3.6, below shows that the same marker comparisons exhibit similar LD. This may be 
due to the program taking only the D‟ value into account. Thus, all the blue blocks, D‟ 
value = 1, are deemed to exhibit strong LD. Interestingly, this method confirmed the 
amount of recombination that occurs at all other blocks.  
 
 
Figure 3.6: LD map of the 13 heterozygous SNP markers under Confidence Bounds setting. A 
simpler method for determining the meaning of each block.  
 
Interestingly, since the commencement of this study, several SNPs have subsequently 
been removed from all databases. SNP 15 (RS117474883) and SNP 20 
(RS118060798) have been retracted from all known databases. The reason for the 
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retraction of these SNPs remains unclear. SNP 13 (MPJ6_OC1004), identified in the 
Japanese population by Itoda et al. (2004), and cited by Shikata et al. (2007), appears 
only in the National Institute of Health Science (NIH) Japanese database. Therefore, 
population data only exists for the Japanese population as this SNP has not been 
investigated in other populations. It has been demonstrated, herein, that a significant 
percentage of the Cape Coloured population are homozygous for the minor allele at 
this locus (Table 3.3). However, the effect that this variation imparts has not yet been 
determined by any preceding study but it has been established that the amino acid 
change is non-synonymous.  
 
The SNPs investigated in this study displayed many similarities to data published for 
the global population. However, for certain SNPs the statistics indicate significant 
differences between our population and other populations. SNPs 1, 2, 4, 6, 7, 11, 14 
and 17 were homozygous in all populations and statistically identical, with the 
exception of the Caucasia American population in which numerous heterozygotes 
occurred across the SNPs. No published population data was available for SNPs 15, 
19 and 20. For SNPS 3, 4, 5, 6, 7, 10, 12, 14 and 17 our population displayed a 
significant amount of similarity to all other populations investigated (Table 3.6) 
(Appendix II). Conversely, SNP 11 was determined to be different, in our population, 
to all other populations as 88% of the population displayed homozygosity for the 
minor allele. Similarly, SNP 18 was shown to be homozygous for the minor allele in 
100% of the Cape Coloured population. However, no other published population data 
exists for this SNP. 
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The online databases (PMT, PharmGKB, and NCBI) provide a vast magnitude of 
information on most of the SNPs analysed herein. However, for some SNPs no 
information is available for any population other than African American. For 
example, the allele frequencies determined for SNP11 and SNP18 were contrary to 
what was published in the databases. This may be said to be a result of the unique 
genetic influence inherited from the indigenous people of the Cape. Currently, many 
studies are in process analysing the same SNPs, using a multitude of methods, for the 
same purpose, to generate population data. More data is constantly being produced. 
This may be a supporting reason for retracting SNPs from the databases if they are 
determined to be the result of an error in a study.  
 
 
In the table 3.3., SNP11 was determined to have an allele frequency exactly opposite 
to that described by the NCBI database for other populations. Only one other 
population in the database exhibits the same allele frequencies as determined herein 
for that SNP.  The dataset used by the database was generated from the genetics 
material sampled from Bushmen of the Northern and Southern Kalahari. It is noted 
that, although they are comprised of two distinct populations, the KhoiSan were 
indigenous to the Cape and form a large part of the genetic ancestry of most Cape 
Coloured people. Therefore, it is not surprising that the data generated herein is 
confirmed by the database specifically for this population and the subject population. 
Moreover, this indicates that the Cape Coloured population is indeed a separate 
population from others, with regard to specific SNPs (SNP18 and SNP11), as these 
variants seem only to be found in this population. 
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3.3.3. Pharmacogenetic Implications of Results 
Cape local communities bear immense genetic diversity. This is a result of the arrival 
of various settlers sent to colonize the Cape. The interbreeding between foreign 
settlers and the indigenous people at the Cape gave rise to a highly genetically diverse 
population over hundreds of years. The resulting population, existing today, thus is 
comprised of several haplotypes. Therefore, it has become apparent that this genetic 
diversity would result in an increase in interindividual variability, specifically with 
regard to drug uptake and metabolism. 
 
When compared to the online databases available it becomes apparent that the Cape 
Coloured population shares largely the same genetic characteristics as the global 
population. It is therefore safe to assume that as a result the interbreeding of various 
ethnicities, a large proportion of the global population is represented in this 
population. Furthermore, only a small percentage of the results do not correspond to 
the global statistics. Twelve of the SNPs were determined to have non-synonymous 
amino acid substitutions. However, published finding for only 7 of these SNPs were 
available from the databases.  
 
SNP1, SNP2 and SNP6, amino acid changes R61C, G220V and G401S respectively, 
have been found to fully abolish OCT1 activity and reduce the uptake of both 
metformin and MPP
+
 in transfected cells (Shu, et al, 2003; Shu, et al, 2007, Tzvetkov 
et al, 2009). SNP4, with amino acid variant S189L and described by Shu, et al. 
(2007), has been determined to reduce the uptake of metformin in transfected cells. It 
has been determined that SNP8 and SNP9 belong to a cluster of single base deletions 
where each deletion causes the same amino acid variation, namely M420del. This 
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cluster has been shown to partially reduce metformin uptake in transfected cells (Shu, 
et al, 2007, Tzvetkov et al, 2009). It has been established that SNP5, amino acid 
variation P341L, described by Shu, et al. (2003), results in reduced MPP
+
 uptake in 
oocytes. Interestingly, SNP5 was determined, in this study, to have a minor allele 
frequency of 1%. Thus, indicating that the polymorphism is present in 1% of the 
samples analysed. However, since all the samples were collected from male donors, 
the effect this polymorphism may have on those individuals remains undetermined. 
 
It may therefore be suggested that having a combination of these 7 SNPs may reduce 
the efficacy of Metformin and increase its toxicity (Shu et al, 2007). It may also be 
suggested that the combination of SNPs may be responsible for individuals to display 
no response to the drug (Tzvetkov et al, 2009).  
 
Interestingly, the individual‟s genotype also has a significant impact on the efficacy of 
the drug (Tzvetkov et al, 2009). In most instances, different effects will be seen for 
homozygous and heterozygous individuals. In a study by Tzvetkov et al. (2009), the 
renal clearance of metformin was determined in relation to the genotype displayed by 
Caucasian individuals. It was determined that 90% of individuals homozygous for the 
minor, or inactive, allele of each SNP displayed a significantly greater rate of renal 
clearance, thus implying a loss of OCT1 activity and by extension a loss in metformin 
uptake. Furthermore, those heterozygous individuals displayed only a slightly 
increased rate of renal clearance. Conversely, for SNP10, it was determined that 
heterozygous individuals displayed a greater increase in the rate of renal clearance 
than those homozygous for the minor allele. 
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The findings presented herein suggest that for many of the drugs regulated and taken 
up by OCT1, the customization with regard to individualised medicine will remain 
constant for many populations across the world. However, it is those minor 
differences which ultimately lead to improved uptake and metabolism of drugs. Thus, 
from a pharmacogenetics stand point, the percentage of the results which do differ 
from published findings will be most crucial to the development of better 
medications. 
 
Since only two of the SNPs differ significantly from the database, and these two are 
primarily found in individuals descendant from Bushmen, it may be suggested that 
these SNPs will ultimately decide the degree of individualisation of specific drugs. 
Furthermore, SNP11 has been determined to be a non-synonymous SNP where the 
amino acid residue at position 160 is altered from Phenylalanine to Leucine. The 
effect that this has on the uptake of any drug, or endogenous compound, has not been 
determined as of yet. It may therefore be speculated, since no finding to the contrary 
have been published yet, that this SNP will require more detailed investigation in 
order to determine its effect. No data has been published for SNP18. Therefore, the 
effect produced by any variation at this site is currently unknown. However, it is 
suggested that future studies conducted should include this SNP in order to 
characterise the effect it causes, if any, since its incidence is relatively high 
specifically in the Cape Coloured population. 
 
3.3.4. Summary 
To summarize, the above mentioned method has proven to be a both rapid and 
accurate method for high throughput genotyping. Very little optimization was 
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required but further optimization of this system is possible. The results obtained were 
of high quality and accurate and showed a great deal of statistical significance. 
Furthermore, the software available for the analysis of population data played a 
pivotal role in the completion of this study and produced excellent results. Moreover, 
the findings presented herein established not only that the Cape Coloured population 
shares genetic polymorphisms with the global population but also that this population 
presented its own challenges and polymorphisms. It may be concluded that the 
importance of population data, from a pharmacogenetic perspective, is critical to the 
improvement of existing medical practices and the development of new ones. 
 
 
 
 
 80 
Chapter Four 
Development of High Resolution Melt Analysis Genotyping 
System 
 
 
4.1. Introduction 
High Resolution Melt (HRM) analysis is a mutation scanning technique which is able 
to monitor the progressive change in fluorescence caused by the release of 
intercalating dye during denaturation (Wittwer et al, 2003). It is an in-tube method 
requiring only the addition of a saturating intercalating dye and a high resolution 
melting step, specified as a stepwise marginal increase in temperature, after PCR 
amplification (Wittwer et al, 2003). 
 
Different PCR products generally have different melting temperatures. This is 
dependant on their GC content, length and sequence (Ririe et al, 1997). Therefore, 
this method presents an ideal means for SNP genotyping since the above mentioned 
parameters are known and a theoretical melting temperature can be calculated. 
Formerly, temperature resolution was limited, making SNP genotyping using this 
method highly inaccurate (von Ahsen et al, 2001). However, with the recent 
introduction of new techniques, assays and dyes, SNP genotyping has become routine 
(Wittwer et al, 2003; Zhou et al, 2005). Most homozygous sequence variants produce 
a melting temperature (Tm) shift when compared to that of the wild type (Liew et al, 
2004; Palais, et al, 2005). In contrast, heterozygotes are not identified by the Tm, but 
by the shape of the melting curve profile (Graham et al, 2005). A growing interest in 
HRM has been observed with many new applications being developed.  
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It is therefore the aim of this study to develop an HRM-based method for SNP 
genotyping and by doing so confirm the newly reported SNPs on exon 4 of OCT1in 
the Cape Coloured population. 
 
 4.2. Materials and Methods 
4.2.1. Sample Collection 
Samples were collected as described in Chapter 1. 
 
4.2.2. DNA Extraction and Quantification 
DNA was extracted and quantified as described in Chapter 1. 
 
4.2.3. Site Selection 
A newly reported 600bp region on exon 4 of the OCT1 gene was selected for pre-
sequencing scanning. This covered two SNP sites, namely RS34163122 and 
RS35446461.  
 
4.2.4. Primer Design 
All DNA samples were diluted to a final concentration of 5 ng.µl
-1
 and used for the 
HRM analysis. The primers used for the HRM analysis are listed in tables 4.1. All 
primers were synthesized by Integrated DNA Technologies (IDT) Munich, Germany. 
Primers were diluted to a working stock of 2 μM.  
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Table 4.4. HRM primer sequences for newly reported Exon 4 SNPs 
SNP Name Sequence Amplicon Size 
RS_34163122  F-CACAAGAGAGAAGCCTGGGAG 320bp 
 
R-GGTACATGATCGCCACCGTTC 
 
   Rs_35446461  F-GAACGGTGGCGATCATGTACC 280bp 
 
R-AGGAAGGGCCTCACCAGTAG   
  
 
4.2.5. HRM Analysis 
HRM was performed using the Quiagen Type-IT kit in a final volume of 10 µl 
according to manufacturer‟s instructions. PCR amplifications were performed using 5 
µl of the Qiagen Type-IT, 2 µM Primers and 15 ng DNA adjusted to a final volume of 
10 µl using RNA-free water. HRM analysis was performed on a RotorGene Q 
(WhiteSci) real-time PCR thermocycler. Two-step thermocycling conditions were as 
follows; 95°C for 10 min, 94°C for 30 s and 55°C for 60 s for a total of 35 cycles, 
followed by  a timed melt beginning at 80°C and sequentially increasing in 
temperature at a rate of 0.1°C to reach a final temperature of 95°C. Melt profiles were 
then analysed using the RotorGene data collection software and ScreenClust HRM 
software (WhiteSci). 
 
4.3. Results and Discussion 
Two newly reported, and non-annotated, SNPs were from exon 4 of the OCT1 gene 
were selected from the UCSF-PMT database. These SNPs were selected as they are 
within 600 bp of each other. The ideal range for HRM-based polymorphism detection 
is approximately 350 bp; therefore, each SNP could be amplified and analysed 
individually at an amplicon size of between 250 and 300 bp.  
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No optimization of the reaction conditions was required. However, primer design 
played a significant role in the successful amplification and melting of the targets. A 
minimum of three primer sets were designed for each SNP. Of the three sets a forward 
and reverse primer set was chosen which displayed the highest specificity, lowest 
amount of complementarity and lowest amount of secondary structure formation. A 
total of 40 samples were genotyped for RS34163122 and 20 samples for 
RS35446461. 
 
The data collection software provided with the RotorGene Q provided an excellent 
insight into the potential of the thermocycler. Without any third party software or 
specifically focused software from WhiteSci, the genotype of each locus could be 
observed. The sensitivity of the thermocycler allowed for the differentiation between 
multiple alleles at a specific locus (Figure 4.2). Furthermore, differentiation between 
homo- and heterozygotes was well observed on the data difference plots (Figure 4.2). 
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Figure 4.1: Raw fluorescence plots for each of the SNP amplifications. A: RS34163122, 6 reactions displayed late amplification where as one displayed no 
amplification. B: RS35446461, only one reaction displayed no amplification. 
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Figure 4.2: RS34163122 HRM mutation screen. Alleles 1 and 2 are indicated at the target site. 
Note a secondary target marked X. 
 
 
In Figure 4.2 a series of peaks are seen. The target, and largest, peak is labelled by 
allele 1. Although the position of the peak for the second allele seems relatively close 
to those of allele 1, it is indicative of the class of the sensitivity of the machine.  
 
However, the difference plot (Figure 4.3) provides a greater detail with reference to 
the difference between wild type and mutant genotypes. In this instance wild type and 
mutant refers to allele 1 and allele 2 respectively. Only the target peak is shown in this 
plot.    
 
Interestingly, a secondary peak was observed (Figure 4.2). This may be indicative of a 
novel SNP within the Cape Coloured population. Further sequencing will be required 
to confirm the presence of a novel SNP. The unlabelled third peak was determined to 
be a non-specific PCR artefact and had no significant detrimental effect on mutation 
scanning. 
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Figure 4.3: Normalised plot (A) and difference plot (B) for RS34163122 using the wild type (WT) 
genotype as a reference. Note the larger divergence depicted by the mutant (Mut) in blue. 
 
 
Figure 4.4: RS35446461 HRM mutation scan. A single target peak is observed. This SNP was 
determined to be homozygous in previous chapters in this study. 
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No significant mutations were detected for RS3544646 (Figure 4.5). Both the 
normalised data and the difference plot data suggest that no mutations were identified. 
Therefore, it is assumed that all samples exhibit the same genotype, homozygosity for 
allele 1. 
 
Figure 4.5: Normalised plot (A) and difference plot (B) for RS3544646. All samples exhibit wild 
type genotype (Alelle 1 homozygous). 
 
The ScreenClust software, supplied by WhiteSci, provided further tools for analysis. 
Using this software, samples can be clustered into specific genotypes (Figure 4.4 and 
4.5). Furthermore, the software also clustered those samples which displayed 
incomplete amplification or no amplification at all. 
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Figure 4.6: Clustered data for RS54163122 using ScreenClust. Note the samples falling inside of 
the blue cluster. These samples underwent incomplete amplification resulting in the formation of 
non-specific or incomplete products. 
 
Figure 4.7: Clustered data for RS35446461 using ScreenClust. Note only one sample appears in 
the red cluster as it did not amplify at all. 
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In Figure 4.6 two samples were found outside of the cluster zones. These samples 
displayed alleles other than the ancestral for RS34163122. Therefore, these samples 
appear at the same position as the red cluster but occur at different melt temperature. 
A similar conclusion may be drawn for the single outlying sample in Figure 4.7. 
However, in this instance a deficiency of initiation of amplification resulted in no 
amplification occurring for this sample. 
 
The purpose of this study was to introduce the precursory design and development of 
an HRM-based genotyping system. From the results obtained it is evident that the 
method presented herein would require optimization in order to compensate for the 
minute differences in in peak position. However, this study serves only to introduce 
the method for HRM genotyping. It is noted that this technique will successfully 
generate SNP data in a low-cost, rapid and proficient manner. In future work the 
addition of multiplex HRM will be introduced in order to develop and provide an 
HRM-based high-throughput genotyping assay.   
 
4.4. Summary 
The method presented herein serves only to introduce the capabilities and possibilities 
of HRM analysis. It is suggested that in future more complex techniques will 
incorporated into this one to develop a more comprehensive genotyping assay. 
However, as an introductory section, the method presented herein is considered to be 
successful and it will be beneficial to further develop the efficacy and sensitivity of 
the assay.  
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Chapter Five 
Conclusion 
 
Genomic diversity within sub-Saharan Africa, and for that matter the entire African 
continent, is relatively under-studied, despite being home to significant portion of 
human genomic diversity (Hardy et al., 2008). South Africa in particular contains a 
wealth of different population groups. The country is indeed home to the indigenous 
Khoisian, Xhosa, Zulu, Venda, Sotho and Pedi groups, the Afrikaners and the Cape 
Coloured, the latter being a uniquely admixed population of immigrant Europeans, 
Asians and the indigenous populations (Hardy et al., 2008). Despite this fact, it is well 
recognized that African populations have been underrepresented in global 
pharmacogenomics research. 
The study of the genetic diversity of the solute carrier transporter genes and its 
pharmacogenetic implications within the South African and Sub-Saharan Africa will 
contribute in filling the gap of missing important pharmacogenetics data from African 
populations (Benjeddou, 2010). This includes establishing baseline frequency 
distribution of previously reported alleles for the SLC22A1, SLC22A2, SLC22A3, 
SLC47A1 and SLC47A2, SLC22A4 and SLC22A5 genes, as well as the discovery of 
new genetic variants within the investigated populations for these members of the 
super-family of solute carrier transporters. 
For the present study, described in this thesis, important population pharmacogenetic 
data was generated for 20 SNP variants from the SLC22A1 gene within the Cape 
Coloured population of South Africa. Among others, allelic and genotypic 
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frequencies, as well as linkage disequilibrium were determined and compared with 
world populations. 
A MAS-PCR genotyping system was successfully designed and optimized for the 
genotyping of 10 SNPs from the SLC22A1gene. The system is made of 2 multiplexes 
each covering 5 SNPs. The system is currently being used to genotype samples from 
the Cape Coloured population as well as other populations. This MAS-PCR system 
could undergo further evaluation, and may be additional optimization and even re-
designing will be needed.  
The SNaPshot® Multiplex System was used as the standard genotyping technique for 
this study. However, it is recommended to continue developing MAS-PCR 
genotyping systems to include more SNPs that are investigated in the project. MAS-
PCR method should be used whenever possible to reduce the cost of genotyping. 
MAS-PCR genotyping systems are well suited for many smaller and less equipped 
laboratories with modest budgets, and give them the opportunity to generate 
population data in a rapid and cost effective manner. 
It is also recommended to develop HRM genotyping systems, which could reduce the 
cost and increase the throughput rate of genotyping. In addition to genotyping, HRM 
analysis can be used to scan large numbers of samples for novel genetic variations.  
Novel genetic variants‟ discovery study should be initiated for the SLC22A1 and 
other SLC members within immigrant and indigenous populations, using a 
combination of HRM scanning and direct sequencing methods. HRM analysis is used 
to scan large numbers of samples for genetic variation. This mutation scanning 
strategy is used to scan DNA samples from many individuals for minor genetic 
variations to identify candidates with genetic variations for full sequencing analysis 
(Vossen et al., 2009). 
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Appendix I 
 
 
Protocols 
 
 
1. Composition of Buffer and Solutions 
Lysis Buffer (stock) 
10 ml 2 M NaCl  
500 μl 1 M Tris-HCL pH = 8 
200 μl 2 M EDTA 
1% SDS 
All dissolved in a volume of 40 ml SABAX water and made up to a final volume of 
50 ml. 
 
Agarose Gel (50 ml) 
1.5g Agarose 
Added to 48.5 ml 1X TBE Buffer 
 
10X TBE Buffer (1L) 
108g Tris Base EDTA 
~55g Boric Acid 
Add Tris Base, EDTA and Boric Acid to 800 ml DI H2O and mix to dissolve. Adjust 
to 1 L with additional DI H2O once dissolved. 
 
1X TBE Buffer (1L) 
100 ml 10X TBE Buffer 
Add TBE to 900 ml DI H2O.  
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20 mgml
-1
 Proteinase K (5ml) 
100 g Proteinase K 
Add Proteinase K to 5 ml DI H2O. 
 
1X EDTA Buffer 
10 ml 10X EDTA 3730 Running buffer 
 Added to 40 ml DI H2O 
 
 
2. DNA Extraction 
 
2.1. Preparation of the lysis buffer 
Add all reagents in 80% of their final volume in bidestilled water. Add the SDS and 
leave in the oven at 60ºC until it is fully dissolved. Transfer the volume to a 
volumetric flask and add the necessary SABAX water to get 100 % desired volume. 
 
2.2. Extraction Procedure 
 Cut off the surface of the swab with a clean scalpel surgery blade. Work on a 
clean surface (sterile Petri dish or small plastic bag) on top of a tray. 
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 Prepare 1.5 or 2ml Eppendorf tubes, and add a volume of lysis buffer and add 
the proteinase K. (e.g add 3 μl PK 20 mg/ml to 600 μl lysis buffer). 
 
 
 Add the little pieces of excised swab to the Eppendorf tubes and vortex for 30 
seconds. Incubate at 56 ºC and leave it overnight. 
 Transfer all the volume to a clean tube.  
 The pieces of swab still have trapped lysis solution with biological material. 
To recover this volume, proceed as follows: 
 Perforate the end of a 0.5 ml tube with a needle (21-22 gauge) 
 
 Place this tube inside a 1.5 ml Eppendorf tube and spin for 1 min in a 
microcentrifuge. Add the collected volume to the previously separated lysis 
material. 
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 Precipitation was done by adding 1/3 volume of 6M NaCl and shaking the 
tube (s) vigoursly for 15 seconds. 
 Centrifuge for 15min at 5000rpm and transfer supernatant with DNA to 
another tube. 
 Add equal volume of  cold isopropanol. Leave at -80ºC for 30 mins or 
overnight at -20ºC.  
 Pellet the DNA by centrifugation: 14,000 rpm 30 minutes. 
 Wash the pellet with 100 ul of 70% ethanol to remove the salts. Centrifugate 
@ 14,000 rpm for 8 minutes to 30 minutes.  
 Dry pellet shortly in SpeedyVac or at 65ºC, prevent that the DNA becomes too 
dry since it will hardly dissolve then. 
 Dissolve DNA in 30 ul of SABAX water. Store at -20ºC. 
 
3. MAS-PCR 
3.1. MAS PCR Primer mix 
Primer mix of Multiplex 1 and 2 markers was set up according to the table below 
 
 Firstly the F1, F2 and R primers synthesized at  Whitehead Scientific was made 
up to a 100 μM of each individual primer from this 3 μl of each the forward 
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and reverse primers is aliquot into a tube labelled mix and resuspended in a 
final volume of 50 μl. This yielded a stock concentration of 33 μM. 
 Then from the 33 μM stock of these primers a working stock was prepared as 
listed below. 
 All the primers must be at the same concentration which in this case is 0.2 μM  
 To ensure that the concentration remains constant in 10 μl PCR reaction a 10 
X mix is prepared. 
  However in the PCR reaction 0.7 is required making the final concentration 
0.7 μM instead of 0.5 μM 
 It is always best to vortex all primers then centrifuging it prior to  making up a  
primer mix 
  
3.3. Agarose Gel Electrophoresis  
 Amplified products are viewed on a 3% agarose gel (made-up in a final 
volume of 50ml) to ensure that the correct amplicon  size was obtained. 
 Flat capped 0.2ml PCR tubes may be used to prepare samples and PCR 
marker. 
 PCR Marker (New England Biolabs) is prepared by adding 2μl of loading 
dye + 3 μl water +1.2 μl PCR marker. 
 Either the 50bp maker or 100bp marker may be used from (NEB) however 
the 50bp marker is preferable.(most of the bands fall between 50 -100bp) 
 Samples are prepared by loading 1.5 μl of PCR product and 2 μl  loading 
dye onto gel. 
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4. SNaPshot®  Protocol 
4.1. Primer mix 
 
Primer mix of Multiplex 1 and 2 markers was set up according to the table below 
 
 Firstly the F and R primers synthesized at  Whitehead Scientific was made up 
to a 100 μM of each individual primer from this 10 μl of both the forward and 
reverse of a  primer is aliquoted into a tube labelled forward and reverse mix 
 
Forward primer 10 μl (100μM) 
Reverse primer 10 μl 
------------------- ------------------------- 
Mix                    20 μl   F +R   final concentration is now 50 μM   
 
 Then from the 50 μM stock of these primers a working stock was prepared as 
listed below. 
 All the primers must be at the same concentration which in this case is 0.5 μM  
 To ensure that the concentration remains constant in 10 μl PCR reaction a 10 
X mix is prepared. 
  However in the PCR reaction 0.7 is required making the final concentration 
0.7 μM instead of 0.5 μM 
 It is always best to vortex all primers then centrifuging it prior to  making up a  
primer mix 
 
4.2. Parameters used 
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 New primer mix was setup for reactions  
 Vortex reagents prior to making up mastermix once all reagents have been 
added, vortex master mix then centrifuge. 
 Then add  7 µl of master mix to the correctly labelled tube  
 Before adding DNA vortex it.(briefly) 
 Once master mix and DNA has been added to all reaction tubes centrifuge the 
tubes then place in the old 96 well PCR machine  
 
4.3. Agarose Gel Electrophoresis  
 
 Amplified products are viewed on a 3% agarose gel (made-up in a final 
volume of 50ml) to ensure that the correct amplicon  size was obtained. 
 Flat capped 0.2ml PCR tubes may be used to prepare samples and PCR 
marker. 
 PCR Marker (New England Biolabs) is prepared by adding 2μl of loading 
dye + 3 μl water +1.2 μl PCR marker. 
 The Hyperladder V marker was used from (Bioline)  
 Samples are prepared by loading 1.5 μl of PCR product and 2 μl  loading 
dye onto gel. 
 
4.3. PCR cleanup  
                                           
 NB : All reactions at this point and thereafter should be done on 
ice 
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 Always work on ice as the enzymes  Sap and Exo are activated at 37˚C                   
 PCR products amplified with Multiplex 1 and 2  are cleaned in the  
following manner: 
 2.05 µl (1unit/µl) SAP (Amersham) and 2.05 µl (10 units/ µl) of EXO I 
(Amersham) are used to treat 5 µl  PCR products for Multiplex I and 2. 
 The samples should then be incubated @ 37˚ C for 1hr and the enzyme 
inactivated @ 75˚ C for 15 min and kept on hold @ 4 ˚ C.             . 
 
4.4. SNaPshot®  reactions 
 
4.4.1. Extension Treatment of multiplex I and II 
 
The Multiplex PCR products which had undergone cleanup treatment with SAP + Exo 
I, are then amplified with extension primers. 
 
 All extension primers were synthesized by Whitehead Scientific 
 These were first  made-up to a 100 μM stock thereafter to 5 μM working stock 
 A primer mix  may be set up containing all extension primers for the 
respective Multiplex (1or 2) in a 0.5ml or 1.5ml tube depending on how many 
reactions are performed. 
 SNaPshot®  Multiplex mix (Applied Bio systems), purified PCR product and 
water are added individually to each correctly labelled tube after the primer 
mix. 
 The  primer mix consist of the following extension primers for Multiplex 1 
and 2 
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4.4.2. Purification of Extension products of  Multiplex 1 and 2 
 
 A volume of 2.05 μl (1unit) of SAP is added to the extension products, which 
is then incubated @ 37 ºC for 1hr, inactivation of enzyme is @ 75 ºC for 15 
min and kept on hold @ 4 ˚ C. 
 After purification samples can be prepared to be run on the 3500 GENETIC 
ANALYZER. 
 
 
4.4.3. Preparation for the Electrophoresis of extension product on 3500 Genetic 
Analyzer 
 
 Extension samples which had undergone SAP treatment are prepared to be run 
on the on 3500 Genetic Analyzer. 
 Samples are loaded into a 96 well plate according to the sample sheet after a 
master mix has been setup.  
 The master mix contains only the size standard (Liz 120) and Hi di 
formamide. 
 The LIZ 120 and Hi di fomamide do not have to be vortexed prior to use. 
 However once the mix has been setup briefly vortex and centrifuge the master 
mix. 
 Each well will receive x µl of the master mix (depending on the amount of 
extension product used Hi di formamide volume will change) thereafter the 
purified extension product is added. 
 The amount of purified extension product may vary for electrophoresis. 
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 Once the plate has been prepared place a cover over.  
 
5. GeneMapper 4.1 Software 
 Open GeneMapper and start a new project. 
 Import the relevant run files. 
 Select an appropriate size standard and analysis procedure (SNaPshot® ). 
 Click the analyse tab to analyse the samples 
 Once the processing has run to completion, each sample can now be checked 
individually for the performance of the mini-sequencing reaction. 
 Visually inspect each sample to call genotypes. 
 Save the project 
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Appendix II 
 
 
Genotypic Data 
 
 
1. Hardy-Weinberg Equilibrium  
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Where genotypes are represented numerically (1=A, 2=C, 3=G, 4=T) 
 
 
 
2. GenePop  Genotypic differentiation (exact G test) 
 
File: 191436 (Title line:"Total 20 SNPs") 
 
Number of populations detected : 6 
Number of loci detected        : 20 
 
Markov chain parameters 
 Dememorisation       : 1000 
 Batches              : 100 
 Iterations per batch : 1000 
 
 
Locus: rs36103319 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          3   3    
          3   4     Total 
 
C         96  4      100 
AA        100 0      100 
CA        99  1      100 
A         100 0      100 
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ME        100 0      100 
P         100 0      100 
 
Total:    595 5      600 
 
P-value = 0.02276    S.E. = 0.00163021 (45744 switches) 
 
Locus: rs12208357 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   4    
          4   4     Total 
 
C         0   100    100 
AA        0   100    100 
CA        7   93     100 
A         0   100    100 
ME        1   99     100 
P         0   100    100 
 
Total:    8   592    600 
 
P-value = 0.00024    S.E. = 0.000174147 (55004 switches) 
 
Locus: rs1867351 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   2   4    
          2   4   4     Total 
 
C         4   28  68     100 
AA        10  34  56     100 
CA        0   35  65     100 
A         30  54  16     100 
ME        44  56  0      100 
P         71  29  0      100 
 
Total:    159 236 205    600 
 
P-value = 0    S.E. = 0 (86330 switches) 
 
Locus: rs34104736 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   2   4    
          2   4   4     Total 
 
C         85  1   14     100 
AA        100 0   0      100 
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CA        99  1   0      100 
A         100 0   0      100 
ME        100 0   0      100 
P         100 0   0      100 
 
Total:    584 2   14     600 
 
P-value = 0    S.E. = 0 (37095 switches) 
 
Locus: rs2282143 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   2   4    
          2   4   4     Total 
 
C         84  15  1      100 
AA        83  17  0      100 
CA        100 0   0      100 
A         80  17  3      100 
ME        100 0   0      100 
P         100 0   0      100 
 
Total:    547 49  4      600 
 
P-value = 0    S.E. = 0 (52291 switches) 
 
Locus: rs34130495 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   3    
          3   3     Total 
 
C         0   100    100 
AA        1   99     100 
CA        2   98     100 
A         0   100    100 
ME        0   100    100 
P         0   100    100 
 
Total:    3   597    600 
 
P-value = 0.43967    S.E. = 0.0043579 (35761 switches) 
 
Locus: rs16891138 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   1    
          1   2     Total 
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C         100 0      100 
AA        93  7      100 
CA        100 0      100 
A         100 0      100 
ME        100 0      100 
P         100 0      100 
 
Total:    593 7      600 
 
P-value = 0    S.E. = 0 (52685 switches) 
 
Locus: rs35167514 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1    
          1     Total 
 
C         100    100 
AA        94     94 
CA        67     67 
A         100    100 
ME        71     71 
P         100    100 
 
Total:    532    532 
 
No table 
 
Locus: rs34305973 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          4    
          4     Total 
 
C         74     74 
AA        94     94 
CA        67     67 
A         100    100 
ME        71     71 
P         100    100 
 
Total:    506    506 
 
No table 
 
Locus: rs2297374 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   2   4    
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          2   4   4     Total 
 
C         73  2   25     100 
AA        71  16  13     100 
CA        77  16  7      100 
A         90  4   6      100 
ME        90  10  0      100 
P         100 0   0      100 
 
Total:    501 48  51     600 
 
P-value = 0    S.E. = 0 (77279 switches) 
 
Locus: rs683369 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   2   3    
          2   3   3     Total 
 
C         12  2   86     100 
AA        99  1   0      100 
CA        88  11  1      100 
A         96  4   0      100 
ME        90  10  0      100 
P         100 0   0      100 
 
Total:    485 28  87     600 
 
P-value = 0    S.E. = 0 (76211 switches) 
 
Locus: rs628031 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   1   1   3    
          1   2   3   3     Total 
 
C         11  1   49  39     100 
AA        6   0   41  53     100 
CA        16  0   48  36     100 
A         9   0   27  64     100 
ME        0   0   43  57     100 
P         0   0   14  86     100 
 
Total:    42  1   222 335    600 
 
P-value = 0    S.E. = 0 (47691 switches) 
 
Locus: MPJ6_O1004 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
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---------------------------------------------------------------------
------------------------------------------- 
          1   1   3    
          1   3   3     Total 
 
C         1   24  75     100 
AA        0   0   0      0 
CA        0   0   0      0 
A         0   0   0      0 
ME        0   0   0      0 
P         0   0   0      0 
 
Total:    1   24  75     100 
 
No information 
 
Locus: rs34205214 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   1   3    
          1   3   3     Total 
 
C         0   0   100    100 
AA        1   4   95     100 
CA        0   0   100    100 
A         0   0   100    100 
ME        0   0   100    100 
P         0   0   100    100 
 
Total:    1   4   595    600 
 
P-value = 0.00075    S.E. = 0.000358272 (21666 switches) 
 
Locus: rs117474883 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2    
          2     Total 
 
C         100    100 
AA        0      0 
CA        0      0 
A         0      0 
ME        0      0 
P         0      0 
 
Total:    100    100 
 
No table 
 
Locus: rs35191146 
================================= 
Pop       Genotypes: 
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          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          3    
          3     Total 
 
C         70     70 
AA        94     94 
CA        67     67 
A         100    100 
ME        71     71 
P         100    100 
 
Total:    502    502 
 
No table 
 
Locus: rs34059508 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   3    
          3   3     Total 
 
C         0   100    100 
AA        0   100    100 
CA        8   92     100 
A         0   100    100 
ME        0   100    100 
P         0   100    100 
 
Total:    8   592    600 
 
P-value = 0    S.E. = 0 (55092 switches) 
 
Locus: rs115733275 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          3   4    
          3   4     Total 
 
C         0   100    100 
AA        98  2      100 
CA        0   0      0 
A         0   0      0 
ME        0   0      0 
P         0   0      0 
 
Total:    98  102    200 
 
P-value = 0    S.E. = 0 (14852 switches) 
 
Locus: rs116824962 
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================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   4    
          2   4     Total 
 
C         100 0      100 
AA        98  2      100 
CA        0   0      0 
A         0   0      0 
ME        0   0      0 
P         0   0      0 
 
Total:    198 2      200 
 
P-value = 0.50935    S.E. = 0.00548779 (8237 switches) 
 
Locus: rs118060798 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1    
          1     Total 
 
C         100    100 
AA        0      0 
CA        0      0 
A         0      0 
ME        0      0 
P         0      0 
 
Total:    100    100 
 
No table 
 
================================= 
 
P-value across all loci 
(Fisher's method) 
----------------------------------------------------- 
Locus          P-Value   
-------------  --------  
rs36103319     0.02276   
rs12208357     0.00024   
rs1867351      0         
rs34104736     0         
rs2282143      0         
rs34130495     0.43967   
rs16891138     0         
rs2297374      0         
rs683369       0         
rs628031       0         
rs34205214     0.00075   
rs34059508     0         
rs115733275    0         
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rs116824962    0.50935   
 
All: Chi2= Infinity (df= 28), highly significant 
 
Normal ending. 
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3. Genotypic differentiation for each population pair (exact G 
test) 
 
File: 181934 (Title line:"Total 20 SNPs") 
 
Number of populations detected : 6 
Number of loci detected        : 20 
 
Markov chain parameters 
 Dememorisation       : 1000 
 Batches              : 100 
 Iterations per batch : 1000 
 
 
Locus: rs36103319 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          3   3    
          3   4     Total 
 
C         96  4      100 
AA        100 0      100 
CA        99  1      100 
A         100 0      100 
ME        100 0      100 
P         100 0      100 
 
Total:    595 5      600 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs36103319   AA        & C          0.12294  0.00166     61897 
rs36103319   CA        & C          0.36892  0.00254     68480 
rs36103319   CA        & AA         1.00000  0.00000     49745 
rs36103319   A         & C          0.12141  0.00168     62129 
rs36103319   A         & AA         No table 
rs36103319   A         & CA         1.00000  0.00000     50107 
rs36103319   ME        & C          0.12081  0.00158     62038 
rs36103319   ME        & AA         No table 
rs36103319   ME        & CA         1.00000  0.00000     50164 
rs36103319   ME        & A          No table 
rs36103319   P         & C          0.11981  0.00173     62141 
rs36103319   P         & AA         No table 
rs36103319   P         & CA         1.00000  0.00000     49960 
rs36103319   P         & A          No table 
rs36103319   P         & ME         No table 
 
Locus: rs12208357 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   4    
          4   4     Total 
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C         0   100    100 
AA        0   100    100 
CA        7   93     100 
A         0   100    100 
ME        1   99     100 
P         0   100    100 
 
Total:    8   592    600 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs12208357   AA        & C          No table 
rs12208357   CA        & C          0.01281  0.00065     72229 
rs12208357   CA        & AA         0.01441  0.00067     72155 
rs12208357   A         & C          No table 
rs12208357   A         & AA         No table 
rs12208357   A         & CA         0.01332  0.00063     71979 
rs12208357   ME        & C          1.00000  0.00000     49801 
rs12208357   ME        & AA         1.00000  0.00000     50358 
rs12208357   ME        & CA         0.06408  0.00159     71954 
rs12208357   ME        & A          1.00000  0.00000     50236 
rs12208357   P         & C          No table 
rs12208357   P         & AA         No table 
rs12208357   P         & CA         0.01297  0.00062     72488 
rs12208357   P         & A          No table 
rs12208357   P         & ME         1.00000  0.00000     49877 
 
Locus: rs1867351 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   2   4    
          2   4   4     Total 
 
C         4   28  68     100 
AA        10  34  56     100 
CA        0   35  65     100 
A         30  54  16     100 
ME        44  56  0      100 
P         71  29  0      100 
 
Total:    159 236 205    600 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs1867351    AA        & C          0.05089  0.00355     81105 
rs1867351    CA        & C          1.00000  0.00000     70699 
rs1867351    CA        & AA         0.02770  0.00257     78786 
rs1867351    A         & C          0.00000  0.00000     85490 
rs1867351    A         & AA         0.00000  0.00000     85588 
rs1867351    A         & CA         0.00000  0.00000     84738 
rs1867351    ME        & C          0.00000  0.00000     85950 
rs1867351    ME        & AA         0.00000  0.00000     85812 
rs1867351    ME        & CA         0.00000  0.00000     85653 
rs1867351    ME        & A          0.00045  0.00017     81950 
rs1867351    P         & C          0.00000  0.00000     86054 
rs1867351    P         & AA         0.00000  0.00000     86242 
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rs1867351    P         & CA         0.00000  0.00000     85982 
rs1867351    P         & A          0.00000  0.00000     82106 
rs1867351    P         & ME         0.00007  0.00005     88566 
 
Locus: rs34104736 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   2   4    
          2   4   4     Total 
 
C         85  1   14     100 
AA        100 0   0      100 
CA        99  1   0      100 
A         100 0   0      100 
ME        100 0   0      100 
P         100 0   0      100 
 
Total:    584 2   14     600 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs34104736   AA        & C          0.00002  0.00002     55687 
rs34104736   CA        & C          0.00000  0.00000     58982 
rs34104736   CA        & AA         1.00000  0.00000     49703 
rs34104736   A         & C          0.00000  0.00000     55842 
rs34104736   A         & AA         No table 
rs34104736   A         & CA         1.00000  0.00000     49872 
rs34104736   ME        & C          0.00000  0.00000     55832 
rs34104736   ME        & AA         No table 
rs34104736   ME        & CA         1.00000  0.00000     49898 
rs34104736   ME        & A          No table 
rs34104736   P         & C          0.00008  0.00006     55955 
rs34104736   P         & AA         No table 
rs34104736   P         & CA         1.00000  0.00000     49833 
rs34104736   P         & A          No table 
rs34104736   P         & ME         No table 
 
Locus: rs2282143 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   2   4    
          2   4   4     Total 
 
C         84  15  1      100 
AA        83  17  0      100 
CA        100 0   0      100 
A         80  17  3      100 
ME        100 0   0      100 
P         100 0   0      100 
 
Total:    547 49  4      600 
 
Locus        Population pair        P-Value  S.E.     Switches 
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-----------  ---------------------  -------  -------  -------- 
rs2282143    AA        & C          1.00000  0.00000     59096 
rs2282143    CA        & C          0.00005  0.00005     56442 
rs2282143    CA        & AA         0.00005  0.00005     80716 
rs2282143    A         & C          0.43272  0.00536     69334 
rs2282143    A         & AA         0.42341  0.00614     67891 
rs2282143    A         & CA         0.00000  0.00000     65942 
rs2282143    ME        & C          0.00000  0.00000     56169 
rs2282143    ME        & AA         0.00000  0.00000     80722 
rs2282143    ME        & CA         No table 
rs2282143    ME        & A          0.00000  0.00000     66024 
rs2282143    P         & C          0.00000  0.00000     56452 
rs2282143    P         & AA         0.00000  0.00000     80631 
rs2282143    P         & CA         No table 
rs2282143    P         & A          0.00000  0.00000     65974 
rs2282143    P         & ME         No table 
 
Locus: rs34130495 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   3    
          3   3     Total 
 
C         0   100    100 
AA        1   99     100 
CA        2   98     100 
A         0   100    100 
ME        0   100    100 
P         0   100    100 
 
Total:    3   597    600 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs34130495   AA        & C          1.00000  0.00000     50117 
rs34130495   CA        & C          0.49770  0.00154     49783 
rs34130495   CA        & AA         1.00000  0.00000     62487 
rs34130495   A         & C          No table 
rs34130495   A         & AA         1.00000  0.00000     49989 
rs34130495   A         & CA         0.49775  0.00164     49849 
rs34130495   ME        & C          No table 
rs34130495   ME        & AA         1.00000  0.00000     49813 
rs34130495   ME        & CA         0.49868  0.00152     49703 
rs34130495   ME        & A          No table 
rs34130495   P         & C          No table 
rs34130495   P         & AA         1.00000  0.00000     50150 
rs34130495   P         & CA         0.49670  0.00161     49771 
rs34130495   P         & A          No table 
rs34130495   P         & ME         No table 
 
Locus: rs16891138 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
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          1   1    
          1   2     Total 
 
C         100 0      100 
AA        93  7      100 
CA        100 0      100 
A         100 0      100 
ME        100 0      100 
P         100 0      100 
 
Total:    593 7      600 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs16891138   AA        & C          0.01354  0.00061     72442 
rs16891138   CA        & C          No table 
rs16891138   CA        & AA         0.01475  0.00068     72436 
rs16891138   A         & C          No table 
rs16891138   A         & AA         0.01396  0.00071     72123 
rs16891138   A         & CA         No table 
rs16891138   ME        & C          No table 
rs16891138   ME        & AA         0.01408  0.00077     72446 
rs16891138   ME        & CA         No table 
rs16891138   ME        & A          No table 
rs16891138   P         & C          No table 
rs16891138   P         & AA         0.01299  0.00065     72346 
rs16891138   P         & CA         No table 
rs16891138   P         & A          No table 
rs16891138   P         & ME         No table 
 
Locus: rs35167514 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1    
          1     Total 
 
C         100    100 
AA        94     94 
CA        67     67 
A         100    100 
ME        71     71 
P         100    100 
 
Total:    532    532 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs35167514   AA        & C          No table 
rs35167514   CA        & C          No table 
rs35167514   CA        & AA         No table 
rs35167514   A         & C          No table 
rs35167514   A         & AA         No table 
rs35167514   A         & CA         No table 
rs35167514   ME        & C          No table 
rs35167514   ME        & AA         No table 
rs35167514   ME        & CA         No table 
rs35167514   ME        & A          No table 
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rs35167514   P         & C          No table 
rs35167514   P         & AA         No table 
rs35167514   P         & CA         No table 
rs35167514   P         & A          No table 
rs35167514   P         & ME         No table 
 
Locus: rs34305973 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          4    
          4     Total 
 
C         74     74 
AA        94     94 
CA        67     67 
A         100    100 
ME        71     71 
P         100    100 
 
Total:    506    506 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs34305973   AA        & C          No table 
rs34305973   CA        & C          No table 
rs34305973   CA        & AA         No table 
rs34305973   A         & C          No table 
rs34305973   A         & AA         No table 
rs34305973   A         & CA         No table 
rs34305973   ME        & C          No table 
rs34305973   ME        & AA         No table 
rs34305973   ME        & CA         No table 
rs34305973   ME        & A          No table 
rs34305973   P         & C          No table 
rs34305973   P         & AA         No table 
rs34305973   P         & CA         No table 
rs34305973   P         & A          No table 
rs34305973   P         & ME         No table 
 
Locus: rs2297374 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   2   4    
          2   4   4     Total 
 
C         73  2   25     100 
AA        71  16  13     100 
CA        77  16  7      100 
A         90  4   6      100 
ME        90  10  0      100 
P         100 0   0      100 
 
Total:    501 48  51     600 
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Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs2297374    AA        & C          0.43133  0.00830     81315 
rs2297374    CA        & C          0.04704  0.00337     80655 
rs2297374    CA        & AA         0.25582  0.00583     81015 
rs2297374    A         & C          0.00051  0.00015     73214 
rs2297374    A         & AA         0.00438  0.00068     79239 
rs2297374    A         & CA         0.09481  0.00366     77061 
rs2297374    ME        & C          0.00000  0.00000     77626 
rs2297374    ME        & AA         0.00006  0.00006     77966 
rs2297374    ME        & CA         0.00386  0.00059     74279 
rs2297374    ME        & A          0.40115  0.00395     70127 
rs2297374    P         & C          0.00000  0.00000     60280 
rs2297374    P         & AA         0.00000  0.00000     76237 
rs2297374    P         & CA         0.00000  0.00000     72123 
rs2297374    P         & A          0.00197  0.00032     61033 
rs2297374    P         & ME         0.00163  0.00027     74721 
 
Locus: rs683369 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   2   3    
          2   3   3     Total 
 
C         12  2   86     100 
AA        99  1   0      100 
CA        88  11  1      100 
A         96  4   0      100 
ME        90  10  0      100 
P         100 0   0      100 
 
Total:    485 28  87     600 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs683369     AA        & C          0.00000  0.00000     69499 
rs683369     CA        & C          0.00000  0.00000     81230 
rs683369     CA        & AA         0.00252  0.00045     55263 
rs683369     A         & C          0.00000  0.00000     74987 
rs683369     A         & AA         0.36991  0.00250     68624 
rs683369     A         & CA         0.05615  0.00261     56595 
rs683369     ME        & C          0.00000  0.00000     80220 
rs683369     ME        & AA         0.01047  0.00065     76960 
rs683369     ME        & CA         0.67670  0.00471     57685 
rs683369     ME        & A          0.16287  0.00302     78611 
rs683369     P         & C          0.00000  0.00000     62775 
rs683369     P         & AA         1.00000  0.00000     50050 
rs683369     P         & CA         0.00054  0.00028     55017 
rs683369     P         & A          0.11895  0.00175     62417 
rs683369     P         & ME         0.00165  0.00021     74767 
 
Locus: rs628031 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
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---------------------------------------------------------------------
------------------------------------------- 
          1   1   1   3    
          1   2   3   3     Total 
 
C         11  1   49  39     100 
AA        6   0   41  53     100 
CA        16  0   48  36     100 
A         9   0   27  64     100 
ME        0   0   43  57     100 
P         0   0   14  86     100 
 
Total:    42  1   222 335    600 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs628031     AA        & C          0.03446  0.00310     63542 
rs628031     CA        & C          0.47494  0.00742     64773 
rs628031     CA        & AA         0.00523  0.00072     83564 
rs628031     A         & C          0.00625  0.00122     63910 
rs628031     A         & AA         0.43979  0.00666     81358 
rs628031     A         & CA         0.00009  0.00005     84236 
rs628031     ME        & C          0.00073  0.00030     62119 
rs628031     ME        & AA         0.24174  0.00672     75208 
rs628031     ME        & CA         0.00031  0.00021     82216 
rs628031     ME        & A          0.90755  0.00180     78317 
rs628031     P         & C          0.00000  0.00000     62188 
rs628031     P         & AA         0.00000  0.00000     74442 
rs628031     P         & CA         0.00000  0.00000     81565 
rs628031     P         & A          0.00001  0.00001     77449 
rs628031     P         & ME         0.00000  0.00000     87605 
 
Locus: MPJ6_O1004 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   1   3    
          1   3   3     Total 
 
C         1   24  75     100 
AA        0   0   0      0 
CA        0   0   0      0 
A         0   0   0      0 
ME        0   0   0      0 
P         0   0   0      0 
 
Total:    1   24  75     100 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
MPJ6_O1004   AA        & C          No table 
MPJ6_O1004   CA        & C          No table 
MPJ6_O1004   CA        & AA         No table 
MPJ6_O1004   A         & C          No table 
MPJ6_O1004   A         & AA         No table 
MPJ6_O1004   A         & CA         No table 
MPJ6_O1004   ME        & C          No table 
MPJ6_O1004   ME        & AA         No table 
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MPJ6_O1004   ME        & CA         No table 
MPJ6_O1004   ME        & A          No table 
MPJ6_O1004   P         & C          No table 
MPJ6_O1004   P         & AA         No table 
MPJ6_O1004   P         & CA         No table 
MPJ6_O1004   P         & A          No table 
MPJ6_O1004   P         & ME         No table 
 
Locus: rs34205214 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   1   3    
          1   3   3     Total 
 
C         0   0   100    100 
AA        1   4   95     100 
CA        0   0   100    100 
A         0   0   100    100 
ME        0   0   100    100 
P         0   0   100    100 
 
Total:    1   4   595    600 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs34205214   AA        & C          0.05774  0.00160     47958 
rs34205214   CA        & C          No table 
rs34205214   CA        & AA         0.05885  0.00164     47743 
rs34205214   A         & C          No table 
rs34205214   A         & AA         0.06126  0.00182     47729 
rs34205214   A         & CA         No table 
rs34205214   ME        & C          No table 
rs34205214   ME        & AA         0.05614  0.00182     47836 
rs34205214   ME        & CA         No table 
rs34205214   ME        & A          No table 
rs34205214   P         & C          No table 
rs34205214   P         & AA         0.05965  0.00194     47774 
rs34205214   P         & CA         No table 
rs34205214   P         & A          No table 
rs34205214   P         & ME         No table 
 
Locus: rs117474883 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2    
          2     Total 
 
C         100    100 
AA        0      0 
CA        0      0 
A         0      0 
ME        0      0 
P         0      0 
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Total:    100    100 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs117474883  AA        & C          No table 
rs117474883  CA        & C          No table 
rs117474883  CA        & AA         No table 
rs117474883  A         & C          No table 
rs117474883  A         & AA         No table 
rs117474883  A         & CA         No table 
rs117474883  ME        & C          No table 
rs117474883  ME        & AA         No table 
rs117474883  ME        & CA         No table 
rs117474883  ME        & A          No table 
rs117474883  P         & C          No table 
rs117474883  P         & AA         No table 
rs117474883  P         & CA         No table 
rs117474883  P         & A          No table 
rs117474883  P         & ME         No table 
 
Locus: rs35191146 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          3    
          3     Total 
 
C         70     70 
AA        94     94 
CA        67     67 
A         100    100 
ME        71     71 
P         100    100 
 
Total:    502    502 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs35191146   AA        & C          No table 
rs35191146   CA        & C          No table 
rs35191146   CA        & AA         No table 
rs35191146   A         & C          No table 
rs35191146   A         & AA         No table 
rs35191146   A         & CA         No table 
rs35191146   ME        & C          No table 
rs35191146   ME        & AA         No table 
rs35191146   ME        & CA         No table 
rs35191146   ME        & A          No table 
rs35191146   P         & C          No table 
rs35191146   P         & AA         No table 
rs35191146   P         & CA         No table 
rs35191146   P         & A          No table 
rs35191146   P         & ME         No table 
 
Locus: rs34059508 
================================= 
Pop       Genotypes: 
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          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   3    
          3   3     Total 
 
C         0   100    100 
AA        0   100    100 
CA        8   92     100 
A         0   100    100 
ME        0   100    100 
P         0   100    100 
 
Total:    8   592    600 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs34059508   AA        & C          No table 
rs34059508   CA        & C          0.00626  0.00039     72084 
rs34059508   CA        & AA         0.00676  0.00048     71967 
rs34059508   A         & C          No table 
rs34059508   A         & AA         No table 
rs34059508   A         & CA         0.00741  0.00049     72238 
rs34059508   ME        & C          No table 
rs34059508   ME        & AA         No table 
rs34059508   ME        & CA         0.00607  0.00050     72173 
rs34059508   ME        & A          No table 
rs34059508   P         & C          No table 
rs34059508   P         & AA         No table 
rs34059508   P         & CA         0.00670  0.00047     72293 
rs34059508   P         & A          No table 
rs34059508   P         & ME         No table 
 
Locus: rs115733275 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          3   4    
          3   4     Total 
 
C         0   100    100 
AA        98  2      100 
CA        0   0      0 
A         0   0      0 
ME        0   0      0 
P         0   0      0 
 
Total:    98  102    200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs115733275  AA        & C          0.00000  0.00000     88436 
rs115733275  CA        & C          No table 
rs115733275  CA        & AA         No table 
rs115733275  A         & C          No table 
rs115733275  A         & AA         No table 
rs115733275  A         & CA         No table 
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rs115733275  ME        & C          No table 
rs115733275  ME        & AA         No table 
rs115733275  ME        & CA         No table 
rs115733275  ME        & A          No table 
rs115733275  P         & C          No table 
rs115733275  P         & AA         No table 
rs115733275  P         & CA         No table 
rs115733275  P         & A          No table 
rs115733275  P         & ME         No table 
 
Locus: rs116824962 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   4    
          2   4     Total 
 
C         100 0      100 
AA        98  2      100 
CA        0   0      0 
A         0   0      0 
ME        0   0      0 
P         0   0      0 
 
Total:    198 2      200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs116824962  AA        & C          0.49813  0.00160     49856 
rs116824962  CA        & C          No table 
rs116824962  CA        & AA         No table 
rs116824962  A         & C          No table 
rs116824962  A         & AA         No table 
rs116824962  A         & CA         No table 
rs116824962  ME        & C          No table 
rs116824962  ME        & AA         No table 
rs116824962  ME        & CA         No table 
rs116824962  ME        & A          No table 
rs116824962  P         & C          No table 
rs116824962  P         & AA         No table 
rs116824962  P         & CA         No table 
rs116824962  P         & A          No table 
rs116824962  P         & ME         No table 
 
Locus: rs118060798 
================================= 
Pop       Genotypes: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1    
          1     Total 
 
C         100    100 
AA        0      0 
CA        0      0 
A         0      0 
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ME        0      0 
P         0      0 
 
Total:    100    100 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs118060798  AA        & C          No table 
rs118060798  CA        & C          No table 
rs118060798  CA        & AA         No table 
rs118060798  A         & C          No table 
rs118060798  A         & AA         No table 
rs118060798  A         & CA         No table 
rs118060798  ME        & C          No table 
rs118060798  ME        & AA         No table 
rs118060798  ME        & CA         No table 
rs118060798  ME        & A          No table 
rs118060798  P         & C          No table 
rs118060798  P         & AA         No table 
rs118060798  P         & CA         No table 
rs118060798  P         & A          No table 
rs118060798  P         & ME         No table 
 
================================= 
 
P-value for each population pair across all loci 
(Fisher's method) 
----------------------------------------------------- 
Population pair               Chi2      df   P-Value 
--------------------          --------  ---  -------- 
C             & AA             Infinity 24   Highly sign. 
C             & CA             Infinity 20   Highly sign. 
AA            & CA            84.75155  24   0.000000 
C             & A              Infinity 14   Highly sign. 
AA            & A              Infinity 16   Highly sign. 
CA            & A              Infinity 20   Highly sign. 
C             & ME             Infinity 16   Highly sign. 
AA            & ME             Infinity 18   Highly sign. 
CA            & ME             Infinity 18   Highly sign. 
A             & ME             Infinity 12   Highly sign. 
C             & P              Infinity 14   Highly sign. 
AA            & P              Infinity 16   Highly sign. 
CA            & P              Infinity 18   Highly sign. 
A             & P              Infinity 10   Highly sign. 
ME            & P              Infinity 10   Highly sign. 
 
Normal ending. 
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4. Genic differentiation for each population pair (exact G test) 
 
File: 182531 (Title line:"Total 20 SNPs") 
 
Number of populations detected : 6 
Number of loci detected        : 20 
 
Markov chain parameters 
 Dememorisation       : 1000 
 Batches              : 100 
 Iterations per batch : 1000 
 
 
Locus: rs36103319 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          3   4     Total 
 
C         196 4      200 
AA        200 0      200 
CA        199 1      200 
A         200 0      200 
ME        200 0      200 
P         200 0      200 
 
Total:    11955      1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs36103319   AA        & C          0.12522  0.00177     62083 
rs36103319   CA        & C          0.37183  0.00259     68588 
rs36103319   CA        & AA         1.00000  0.00000     49764 
rs36103319   A         & C          0.12345  0.00163     62297 
rs36103319   A         & AA         No table 
rs36103319   A         & CA         1.00000  0.00000     50131 
rs36103319   ME        & C          0.12244  0.00165     62201 
rs36103319   ME        & AA         No table 
rs36103319   ME        & CA         1.00000  0.00000     50164 
rs36103319   ME        & A          No table 
rs36103319   P         & C          0.12202  0.00170     62396 
rs36103319   P         & AA         No table 
rs36103319   P         & CA         1.00000  0.00000     49962 
rs36103319   P         & A          No table 
rs36103319   P         & ME         No table 
 
Locus: rs12208357 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   4     Total 
 
C         0   200    200 
AA        0   200    200 
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CA        7   193    200 
A         0   200    200 
ME        1   199    200 
P         0   200    200 
 
Total:    8   1192   1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs12208357   AA        & C          No table 
rs12208357   CA        & C          0.01382  0.00066     72433 
rs12208357   CA        & AA         0.01498  0.00070     72365 
rs12208357   A         & C          No table 
rs12208357   A         & AA         No table 
rs12208357   A         & CA         0.01405  0.00063     72216 
rs12208357   ME        & C          1.00000  0.00000     49890 
rs12208357   ME        & AA         1.00000  0.00000     50035 
rs12208357   ME        & CA         0.06622  0.00165     72305 
rs12208357   ME        & A          1.00000  0.00000     50037 
rs12208357   P         & C          No table 
rs12208357   P         & AA         No table 
rs12208357   P         & CA         0.01351  0.00060     72704 
rs12208357   P         & A          No table 
rs12208357   P         & ME         1.00000  0.00000     50438 
 
Locus: rs1867351 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   4     Total 
 
C         36  164    200 
AA        54  146    200 
CA        35  165    200 
A         114 86     200 
ME        144 56     200 
P         171 29     200 
 
Total:    554 646    1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs1867351    AA        & C          0.04557  0.00324     90261 
rs1867351    CA        & C          1.00000  0.00000     89524 
rs1867351    CA        & AA         0.03034  0.00259     90623 
rs1867351    A         & C          0.00000  0.00000     91989 
rs1867351    A         & AA         0.00000  0.00000     92061 
rs1867351    A         & CA         0.00000  0.00000     92009 
rs1867351    ME        & C          0.00000  0.00000     91901 
rs1867351    ME        & AA         0.00000  0.00000     91953 
rs1867351    ME        & CA         0.00000  0.00000     91833 
rs1867351    ME        & A          0.00291  0.00063     91518 
rs1867351    P         & C          0.00000  0.00000     91937 
rs1867351    P         & AA         0.00000  0.00000     92119 
rs1867351    P         & CA         0.00000  0.00000     92152 
rs1867351    P         & A          0.00000  0.00000     91305 
rs1867351    P         & ME         0.00211  0.00073     90230 
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Locus: rs34104736 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   4     Total 
 
C         171 29     200 
AA        200 0      200 
CA        199 1      200 
A         200 0      200 
ME        200 0      200 
P         200 0      200 
 
Total:    117030     1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs34104736   AA        & C          0.00000  0.00000     85353 
rs34104736   CA        & C          0.00000  0.00000     84726 
rs34104736   CA        & AA         1.00000  0.00000     49991 
rs34104736   A         & C          0.00000  0.00000     85048 
rs34104736   A         & AA         No table 
rs34104736   A         & CA         1.00000  0.00000     50002 
rs34104736   ME        & C          0.00000  0.00000     85103 
rs34104736   ME        & AA         No table 
rs34104736   ME        & CA         1.00000  0.00000     49986 
rs34104736   ME        & A          No table 
rs34104736   P         & C          0.00000  0.00000     84800 
rs34104736   P         & AA         No table 
rs34104736   P         & CA         1.00000  0.00000     49774 
rs34104736   P         & A          No table 
rs34104736   P         & ME         No table 
 
Locus: rs2282143 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   4     Total 
 
C         183 17     200 
AA        183 17     200 
CA        200 0      200 
A         177 23     200 
ME        200 0      200 
P         200 0      200 
 
Total:    114357     1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs2282143    AA        & C          1.00000  0.00000     85848 
rs2282143    CA        & C          0.00000  0.00000     81000 
rs2282143    CA        & AA         0.00003  0.00002     81096 
rs2282143    A         & C          0.40702  0.00524     86616 
rs2282143    A         & AA         0.40945  0.00518     86696 
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rs2282143    A         & CA         0.00000  0.00000     83345 
rs2282143    ME        & C          0.00000  0.00000     81007 
rs2282143    ME        & AA         0.00000  0.00000     81299 
rs2282143    ME        & CA         No table 
rs2282143    ME        & A          0.00000  0.00000     83476 
rs2282143    P         & C          0.00000  0.00000     81109 
rs2282143    P         & AA         0.00001  0.00001     81173 
rs2282143    P         & CA         No table 
rs2282143    P         & A          0.00000  0.00000     83436 
rs2282143    P         & ME         No table 
 
Locus: rs34130495 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   3     Total 
 
C         0   200    200 
AA        1   199    200 
CA        2   198    200 
A         0   200    200 
ME        0   200    200 
P         0   200    200 
 
Total:    3   1197   1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs34130495   AA        & C          1.00000  0.00000     50006 
rs34130495   CA        & C          0.49850  0.00163     49791 
rs34130495   CA        & AA         1.00000  0.00000     62210 
rs34130495   A         & C          No table 
rs34130495   A         & AA         1.00000  0.00000     49867 
rs34130495   A         & CA         0.50206  0.00177     49820 
rs34130495   ME        & C          No table 
rs34130495   ME        & AA         1.00000  0.00000     50027 
rs34130495   ME        & CA         0.49876  0.00143     50072 
rs34130495   ME        & A          No table 
rs34130495   P         & C          No table 
rs34130495   P         & AA         1.00000  0.00000     50169 
rs34130495   P         & CA         0.49787  0.00161     49979 
rs34130495   P         & A          No table 
rs34130495   P         & ME         No table 
 
Locus: rs16891138 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   2     Total 
 
C         200 0      200 
AA        193 7      200 
CA        200 0      200 
A         200 0      200 
ME        200 0      200 
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P         200 0      200 
 
Total:    11937      1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs16891138   AA        & C          0.01489  0.00071     72506 
rs16891138   CA        & C          No table 
rs16891138   CA        & AA         0.01485  0.00073     72511 
rs16891138   A         & C          No table 
rs16891138   A         & AA         0.01332  0.00065     72472 
rs16891138   A         & CA         No table 
rs16891138   ME        & C          No table 
rs16891138   ME        & AA         0.01571  0.00067     72259 
rs16891138   ME        & CA         No table 
rs16891138   ME        & A          No table 
rs16891138   P         & C          No table 
rs16891138   P         & AA         0.01412  0.00071     72515 
rs16891138   P         & CA         No table 
rs16891138   P         & A          No table 
rs16891138   P         & ME         No table 
 
Locus: rs35167514 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1     Total 
 
C         200    200 
AA        194    194 
CA        165    165 
A         200    200 
ME        157    157 
P         200    200 
 
Total:    1116   1116 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs35167514   AA        & C          No table 
rs35167514   CA        & C          No table 
rs35167514   CA        & AA         No table 
rs35167514   A         & C          No table 
rs35167514   A         & AA         No table 
rs35167514   A         & CA         No table 
rs35167514   ME        & C          No table 
rs35167514   ME        & AA         No table 
rs35167514   ME        & CA         No table 
rs35167514   ME        & A          No table 
rs35167514   P         & C          No table 
rs35167514   P         & AA         No table 
rs35167514   P         & CA         No table 
rs35167514   P         & A          No table 
rs35167514   P         & ME         No table 
 
Locus: rs34305973 
================================= 
Pop       Alleles: 
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          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          4     Total 
 
C         174    174 
AA        194    194 
CA        165    165 
A         200    200 
ME        157    157 
P         200    200 
 
Total:    1090   1090 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs34305973   AA        & C          No table 
rs34305973   CA        & C          No table 
rs34305973   CA        & AA         No table 
rs34305973   A         & C          No table 
rs34305973   A         & AA         No table 
rs34305973   A         & CA         No table 
rs34305973   ME        & C          No table 
rs34305973   ME        & AA         No table 
rs34305973   ME        & CA         No table 
rs34305973   ME        & A          No table 
rs34305973   P         & C          No table 
rs34305973   P         & AA         No table 
rs34305973   P         & CA         No table 
rs34305973   P         & A          No table 
rs34305973   P         & ME         No table 
 
Locus: rs2297374 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   4     Total 
 
C         148 52     200 
AA        158 42     200 
CA        170 30     200 
A         184 16     200 
ME        190 10     200 
P         200 0      200 
 
Total:    1050150    1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs2297374    AA        & C          0.28067  0.00740     90733 
rs2297374    CA        & C          0.00960  0.00138     89892 
rs2297374    CA        & AA         0.16478  0.00559     89409 
rs2297374    A         & C          0.00000  0.00000     89247 
rs2297374    A         & AA         0.00056  0.00025     88796 
rs2297374    A         & CA         0.04433  0.00260     87261 
rs2297374    ME        & C          0.00000  0.00000     89051 
rs2297374    ME        & AA         0.00000  0.00000     88094 
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rs2297374    ME        & CA         0.00075  0.00021     87129 
rs2297374    ME        & A          0.31630  0.00488     83817 
rs2297374    P         & C          0.00000  0.00000     88136 
rs2297374    P         & AA         0.00000  0.00000     87098 
rs2297374    P         & CA         0.00000  0.00000     85029 
rs2297374    P         & A          0.00001  0.00001     79755 
rs2297374    P         & ME         0.00199  0.00028     75083 
 
Locus: rs683369 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   3     Total 
 
C         26  174    200 
AA        199 1      200 
CA        187 13     200 
A         196 4      200 
ME        190 10     200 
P         200 0      200 
 
Total:    998 202    1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs683369     AA        & C          0.00000  0.00000     92233 
rs683369     CA        & C          0.00000  0.00000     92007 
rs683369     CA        & AA         0.00146  0.00023     78805 
rs683369     A         & C          0.00000  0.00000     92098 
rs683369     A         & AA         0.37015  0.00217     68680 
rs683369     A         & CA         0.04415  0.00173     81316 
rs683369     ME        & C          0.00000  0.00000     92228 
rs683369     ME        & AA         0.01018  0.00076     77061 
rs683369     ME        & CA         0.66415  0.00338     83528 
rs683369     ME        & A          0.17146  0.00264     78698 
rs683369     P         & C          0.00000  0.00000     91896 
rs683369     P         & AA         1.00000  0.00000     50011 
rs683369     P         & CA         0.00024  0.00008     78631 
rs683369     P         & A          0.12106  0.00163     62188 
rs683369     P         & ME         0.00162  0.00023     75047 
 
Locus: rs628031 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   2   3     Total 
 
C         72  1   127    200 
AA        53  0   147    200 
CA        80  0   120    200 
A         45  0   155    200 
ME        43  0   157    200 
P         14  0   186    200 
 
Total:    307 1   892    1200 
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Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs628031     AA        & C          0.03915  0.00558     62324 
rs628031     CA        & C          0.48299  0.01367     62541 
rs628031     CA        & AA         0.00625  0.00114     91683 
rs628031     A         & C          0.00403  0.00155     62197 
rs628031     A         & AA         0.41825  0.00723     90746 
rs628031     A         & CA         0.00008  0.00008     91554 
rs628031     ME        & C          0.00107  0.00048     62011 
rs628031     ME        & AA         0.27639  0.00836     90830 
rs628031     ME        & CA         0.00008  0.00005     91500 
rs628031     ME        & A          0.90381  0.00189     90258 
rs628031     P         & C          0.00000  0.00000     62068 
rs628031     P         & AA         0.00000  0.00000     89478 
rs628031     P         & CA         0.00000  0.00000     90710 
rs628031     P         & A          0.00000  0.00000     88996 
rs628031     P         & ME         0.00001  0.00001     88887 
 
Locus: MPJ6_O1004 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   3     Total 
 
C         26  174    200 
AA        0   0      0 
CA        0   0      0 
A         0   0      0 
ME        0   0      0 
P         0   0      0 
 
Total:    26  174    200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
MPJ6_O1004   AA        & C          No table 
MPJ6_O1004   CA        & C          No table 
MPJ6_O1004   CA        & AA         No table 
MPJ6_O1004   A         & C          No table 
MPJ6_O1004   A         & AA         No table 
MPJ6_O1004   A         & CA         No table 
MPJ6_O1004   ME        & C          No table 
MPJ6_O1004   ME        & AA         No table 
MPJ6_O1004   ME        & CA         No table 
MPJ6_O1004   ME        & A          No table 
MPJ6_O1004   P         & C          No table 
MPJ6_O1004   P         & AA         No table 
MPJ6_O1004   P         & CA         No table 
MPJ6_O1004   P         & A          No table 
MPJ6_O1004   P         & ME         No table 
 
Locus: rs34205214 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
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---------------------------------------------------------------------
------------------------------------------- 
          1   3     Total 
 
C         0   200    200 
AA        6   194    200 
CA        0   200    200 
A         0   200    200 
ME        0   200    200 
P         0   200    200 
 
Total:    6   1194   1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs34205214   AA        & C          0.03003  0.00099     68537 
rs34205214   CA        & C          No table 
rs34205214   CA        & AA         0.03039  0.00109     68539 
rs34205214   A         & C          No table 
rs34205214   A         & AA         0.03018  0.00101     68757 
rs34205214   A         & CA         No table 
rs34205214   ME        & C          No table 
rs34205214   ME        & AA         0.02986  0.00099     68697 
rs34205214   ME        & CA         No table 
rs34205214   ME        & A          No table 
rs34205214   P         & C          No table 
rs34205214   P         & AA         0.02982  0.00094     68773 
rs34205214   P         & CA         No table 
rs34205214   P         & A          No table 
rs34205214   P         & ME         No table 
 
Locus: rs117474883 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2     Total 
 
C         200    200 
AA        0      0 
CA        0      0 
A         0      0 
ME        0      0 
P         0      0 
 
Total:    200    200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs117474883  AA        & C          No table 
rs117474883  CA        & C          No table 
rs117474883  CA        & AA         No table 
rs117474883  A         & C          No table 
rs117474883  A         & AA         No table 
rs117474883  A         & CA         No table 
rs117474883  ME        & C          No table 
rs117474883  ME        & AA         No table 
rs117474883  ME        & CA         No table 
rs117474883  ME        & A          No table 
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rs117474883  P         & C          No table 
rs117474883  P         & AA         No table 
rs117474883  P         & CA         No table 
rs117474883  P         & A          No table 
rs117474883  P         & ME         No table 
 
Locus: rs35191146 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          3     Total 
 
C         169    169 
AA        194    194 
CA        165    165 
A         200    200 
ME        157    157 
P         200    200 
 
Total:    1085   1085 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs35191146   AA        & C          No table 
rs35191146   CA        & C          No table 
rs35191146   CA        & AA         No table 
rs35191146   A         & C          No table 
rs35191146   A         & AA         No table 
rs35191146   A         & CA         No table 
rs35191146   ME        & C          No table 
rs35191146   ME        & AA         No table 
rs35191146   ME        & CA         No table 
rs35191146   ME        & A          No table 
rs35191146   P         & C          No table 
rs35191146   P         & AA         No table 
rs35191146   P         & CA         No table 
rs35191146   P         & A          No table 
rs35191146   P         & ME         No table 
 
Locus: rs34059508 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1   3     Total 
 
C         0   200    200 
AA        0   200    200 
CA        8   192    200 
A         0   200    200 
ME        0   200    200 
P         0   200    200 
 
Total:    8   1192   1200 
 
Locus        Population pair        P-Value  S.E.     Switches 
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-----------  ---------------------  -------  -------  -------- 
rs34059508   AA        & C          No table 
rs34059508   CA        & C          0.00788  0.00052     72145 
rs34059508   CA        & AA         0.00784  0.00051     72516 
rs34059508   A         & C          No table 
rs34059508   A         & AA         No table 
rs34059508   A         & CA         0.00833  0.00061     72260 
rs34059508   ME        & C          No table 
rs34059508   ME        & AA         No table 
rs34059508   ME        & CA         0.00780  0.00051     72173 
rs34059508   ME        & A          No table 
rs34059508   P         & C          No table 
rs34059508   P         & AA         No table 
rs34059508   P         & CA         0.00725  0.00053     72453 
rs34059508   P         & A          No table 
rs34059508   P         & ME         No table 
 
Locus: rs115733275 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          3   4     Total 
 
C         0   200    200 
AA        196 4      200 
CA        0   0      0 
A         0   0      0 
ME        0   0      0 
P         0   0      0 
 
Total:    196 204    400 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs115733275  AA        & C          0.00000  0.00000     92215 
rs115733275  CA        & C          No table 
rs115733275  CA        & AA         No table 
rs115733275  A         & C          No table 
rs115733275  A         & AA         No table 
rs115733275  A         & CA         No table 
rs115733275  ME        & C          No table 
rs115733275  ME        & AA         No table 
rs115733275  ME        & CA         No table 
rs115733275  ME        & A          No table 
rs115733275  P         & C          No table 
rs115733275  P         & AA         No table 
rs115733275  P         & CA         No table 
rs115733275  P         & A          No table 
rs115733275  P         & ME         No table 
 
Locus: rs116824962 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          2   4     Total 
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C         200 0      200 
AA        196 4      200 
CA        0   0      0 
A         0   0      0 
ME        0   0      0 
P         0   0      0 
 
Total:    396 4      400 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs116824962  AA        & C          0.12076  0.00154     62329 
rs116824962  CA        & C          No table 
rs116824962  CA        & AA         No table 
rs116824962  A         & C          No table 
rs116824962  A         & AA         No table 
rs116824962  A         & CA         No table 
rs116824962  ME        & C          No table 
rs116824962  ME        & AA         No table 
rs116824962  ME        & CA         No table 
rs116824962  ME        & A          No table 
rs116824962  P         & C          No table 
rs116824962  P         & AA         No table 
rs116824962  P         & CA         No table 
rs116824962  P         & A          No table 
rs116824962  P         & ME         No table 
 
Locus: rs118060798 
================================= 
Pop       Alleles: 
          -----------------------------------------------------------
---------------------------------------------------------------------
---------------------------------------------------------------------
------------------------------------------- 
          1     Total 
 
C         200    200 
AA        0      0 
CA        0      0 
A         0      0 
ME        0      0 
P         0      0 
 
Total:    200    200 
 
Locus        Population pair        P-Value  S.E.     Switches 
-----------  ---------------------  -------  -------  -------- 
rs118060798  AA        & C          No table 
rs118060798  CA        & C          No table 
rs118060798  CA        & AA         No table 
rs118060798  A         & C          No table 
rs118060798  A         & AA         No table 
rs118060798  A         & CA         No table 
rs118060798  ME        & C          No table 
rs118060798  ME        & AA         No table 
rs118060798  ME        & CA         No table 
rs118060798  ME        & A          No table 
rs118060798  P         & C          No table 
rs118060798  P         & AA         No table 
rs118060798  P         & CA         No table 
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rs118060798  P         & A          No table 
rs118060798  P         & ME         No table 
 
================================= 
 
P-value for each population pair across all loci 
(Fisher's method) 
----------------------------------------------------- 
Population pair               Chi2      df   P-Value 
--------------------          --------  ---  -------- 
C             & AA             Infinity 24   Highly sign. 
C             & CA             Infinity 20   Highly sign. 
AA            & CA            88.14038  24   0.000000 
C             & A              Infinity 14   Highly sign. 
AA            & A              Infinity 16   Highly sign. 
CA            & A              Infinity 20   Highly sign. 
C             & ME             Infinity 16   Highly sign. 
AA            & ME             Infinity 18   Highly sign. 
CA            & ME             Infinity 18   Highly sign. 
A             & ME             Infinity 12   Highly sign. 
C             & P              Infinity 14   Highly sign. 
AA            & P              Infinity 16   Highly sign. 
CA            & P              Infinity 18   Highly sign. 
A             & P              Infinity 10   Highly sign. 
ME            & P             60.637885 10   0.000000 
 
Normal ending. 
 
 
 
 
 
 
